INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR This application claims priority to the provisional application Serial No. 60/730,991 filed on October 28,2005. FIELD OF INVENTION The present invention relates to prodrugs of urea containing compounds, pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful for treating pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by vanilloid receptor activity. The compounds of the present invention have better physicochemical properties permitting more active drug to be available. Background of the Invention Nociceptors are primary sensory afferent (C and AS fibers) neurons that are activated by a wide variety of noxious stimuli including chemical, mechanical, thermal, and proton (pH < 6) modalities. The lipophillic vanilloid, capsaicin, activates primary sensory fibers via a specific cell surface capsaicin receptor, cloned as TRPVl. The intradermal administration of capsaicin is characterized by an initial burning or hot sensation followed by a prolonged period of analgesia. The analgesic component of TRPVl receptor activation is thought to be mediated by a capsaicin-induced desensitization of the primary sensory afferent terminal. Thus, the long lasting anti-nociceptive effects of capsaicin have prompted the clinical use of capsaicin analogs as analgesic agents. Further, capsazepine, a capsaicin receptor antagonist can reduce inflammation-induced hyperalgesia in animal models. TRPVl receptors are also localized on sensory afferents, which innervate the bladder. Capsaicin or resiniferatoxin has been shown to ameliorate incontinence symptoms upon injection into the bladder. The TRPVl receptor has been called a "polymodal detector" of noxious stimuli since it can be activated in several ways. The receptor channel is activated by capsaicin and other vanilloids and thus is classified as a ligand-gated ion channel. TRPVl receptor activation by capsaicin can be blocked by the competitive TRPVl receptor antagonist, capsazepine. The channel can also be activated by protons and heat. Under mildly acidic conditions (pH 6-7), the affinity of capsaicin for the receptor is increased, whereas at pH <6, direct activation of the channel occurs. In addition, when membrane temperature reaches 43 °C, the channel is opened. Thus heat can directly gate the channel in the absence of ligand. The capsaicin analog, capsazepine, which is a competitive antagonist of capsaicin, blocks activation of the channel in response to capsaicin, acid, or heat. The channel is a nonspecific cation conductor. Both extracellular sodium and calcium enter through the channel pore, resulting in cell membrane depolarization. This depolarization increases neuronal excitability, leading to action potential firing and transmission of a noxious nerve impulse to the spinal cord. In addition, depolarization of the peripheral terminal can lead to release of inflammatory peptides such as, but not limited to, substance P and CGRP, leading to enhanced peripheral sensitization of tissue. Recently, two groups have reported the generation of a "knock-out" mouse lacking the TRPV1 receptor (TRPV1 (-/-)). Electrophysiological studies of sensory neurons (dorsal root ganglia) from these animals revealed a marked absence of responses evoked by noxious stimuli including capsaicin, heat, and reduced pH. These animals did not display any overt signs of behavioral impairment and showed no differences in responses to acute non-noxious thermal and mechanical stimulation relative to wild-type mice. The TRPV1 (-/-) mice also did not show reduced sensitivity to nerve injury-induced mechanical or thermal nociception. However, the TRPV1 knock-out mice were insensitive to the noxious effects of intradermal capsaicin, exposure to intense heat (50-55°C), and failed to develop thermal hyperalgesia following the intradermal administration of carrageenan. The compounds of the present invention are novel TRPV1 antagonists and have utility in for treating pain, bladder overactivity, urinary incontinence, and other disorders associated with pain that are caused by or exacerbated by vanilloid receptor activity. Summary of the Present Invention The present invention discloses prodrugs of urea containing compounds, pharmaceutically acceptable salts and pharmaceutical compositions thereof. More particularly, the present invention is directed to compounds of formula -O- (Formula Removed) or a pharmaceutically acceptable salt, prodrug, salt of a prodrug or a combination thereof, wherein A is (Formula Removed) R1 is alkyl, cycloalkyl, alkenyl; halogen or haloalkyl; R2 is hydrogen or heterocyclealkyl wherein the heterocycle moiety of the heterocyclealkyl is unsubstituted or substituted with 1,2,3 or 4 substituents selected from the group consisting of alkyl, -alkyl-ORB, and -alkyl-N(RB)2; R3is (Formula Removed) wherein R, is -C-O--0-(CH2)mR5, -C-O-(CH2)n-R6, -(CH2)r-R7, -C-O-R8, or -CH2C(H)(OH)R9 when R2 is hydrogen; or R4 is hydrogen when R2 is heterocyclealkyl; wherein the heterocycle moiety of the heterocyclealkyl is unsubstituted or substituted with 1,2, 3 or 4 substituents selected from the group consisting of alkyl, -alkyl-ORB, and -alkyl-N(RB)2; mis 1,2, or 3; nisi, 2 or 3; ris 1,2 or 3; tisO, 1,2, 3 or 4; uisO, 1,2 or 3; R5 is alkyl, -0-P-O-(ORA)(ORA), -P-O-(ORA)(ORA), -ORA, -OC-O-(RA), heterocycle, -C-O-ORA, -C-O-N(RB)2, -C-O-(RA), -NRARB, or -N(RB)C-O-ORA, Re is alkyl, -OC-O-(RA), -ORA, -C-O-ORA> -NRARB, -OP-O-(ORA)(ORA), or -PCOXORAXORA); R7 is alkoxy, heterocycle, -OC-O-(RA), -OC-O-(hydroxyalkyl), -OP(O)(ORA)(ORA), or-P-O-(ORA)(ORA), R8 is heterocycle or N(Rsa)(R8b) wherein R8a and R8b are independently hydrogen or alkyl; R9 is alkoxyalkyl, -C-O-ORA, -alkyl-N(RB)C-O-ORA) or heterocyclealkyl; R10o is alkyl; each occurence of R11 are independently hydrogen, alkyl or aryl, or two R11 groups that are attached to a single carbon atom together form a cycloalkyl ring; RA is hydrogen, alkyl, alkoxyalkyl, aryl or arylalkyl; RB is hydrogen or alkyl; the heterocycle and the heterocycle moiety of the heterocyclealkyl, represented by R5, R7, R8, and R9, are each independently substituted with 0,1,2 or 3 substituents independently selected from the group consisting of alkyl, haloalkyl, alkoxy, haloalkoxy, -C-O-OH, -alkyl-C-O-OH, and -N(ZA)(ZB); ZA and ZB are each independently hydrogen, alkyl, -C-O-alkyl, formyl, aryl, or arylalkyl; and the aryl and the aryl moiety of the arylalkyl, represented by RA ZA and ZB are each independently substituted with 0,1,2 or 3 substituents selected from the group consisting of alkyl, haloalkyl, alkoxy and haloalkoxy. The compounds of the present invention are useful for treating pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by vaniUoid receptor activity. Also described are pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds of formula (I), or a therapeutically acceptable salt, solvate, or combination thereof, and a pharmaceutically acceptable carrier. One particular embodiment of the present invention describes a method of treating a disease or preventing disorders that may be ameliorated by inhibiting vanilloid receptor subtype 1 activity in a mammal comprising administering a therapeutically effective amount of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof. The compounds of formula (I) may be used in the manufacture of a medicament for the treatment or prevention of a disease or disorder that may be ameliorated by inhibiting vanilloid receptor subtype 1 activity. Furthermore, the disclosed compounds of formula (I) are useful in treating a disease or a disorder, wherein the disease or disorder is associated with pain, inflammation, urinary incontinence and bladder dysfunction. The disclosed methods of treating or preventing disease or disorder associated with pain wherein the pain is neuropathic pain, inflammatory pain, or both, which method comprises administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. There is also disclosed methods of treating or preventing a disease or disorder associated with bladder overactivity or urinary incontinence, or both, which method comprises aiiministering a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof. Detailed Description of the Invention Compounds of the invention have the formula (I) as described above. In general, the compounds of formula (I) can include, but are not limited to, compounds in which A is (Formula Removed) More particularly, compounds of formula (I) contain A which is (Formula Removed) In another series of embodiments, compounds of formula (I) contain A which is In a further series of embodiments, compounds of formula (I) contain A which is (Formula Removed) In yet another series of embodiments, compounds of formula (I) contain A which is (Formula Removed) Lastly in yet another series of embodiments, compounds of formula (I) contain A which is (Formula Removed) For each substructure as defined by ring A, there exist the following embodiments which further define the scope of the compounds of the present invention. These further embodiments are contemplated to apply to each series of compounds of the present invention defined under ring A. In one embodiment there is described compounds of formula -O- wherein R1 is alkyl, cycloalkyl, halogen or haloalkyl, R2 is hydrogen or heterocyclealkyl, R3 is selected from the groups (Formula Removed) and R4 is selected form the group consisting of-C-O--0-(CH2)mRs, -C-O-(CH2)n-R6, -(CH2)r-R7, -C-O-Rg, or -CH2C(H)(OH)R9 when R2 is hydrogen. Compounds of the invention include those wherein R1 is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R2 is hydrogen, R3 is (Formula Removed) and R4 is -(CH2)rR7, in which R7 selected from the group consisting of heterocycle, -OC-O-(RA), -OC-O-(hydroxyalkyl), and -P-O-(ORA)(ORA). Preferred compounds include those in which R7 is -O.C-O-(RA), and RA is hydrogen or those in which R7 is -OC-O-(hydroxyalkyl). Other compounds of the present invention include those wherein Rt is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R2 is hydrogen, R3 is (Formula Removed) , and R4 is -C-O-(CH2)n-R6, wherein R6 is selected from the group consisting of is -OC-O-(RA), -ORA, -C-O-ORA) -NRARB, -OP-O-(ORA)(ORA) or -P-O-(ORA)(ORA). Examples of compounds of the present invention are those in which RA is hydrogen, alkyl, aryl or arylalkyl. Other compounds of the present invention include those wherein R1 is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R2 is hydrogen, R3 is (Formula Removed) and R4 is -CH2C(H)(OH)R9, wherein R9 is selected from the group consisting of alkoxyalkyl, -C(O)RA -alkyl-N(RB)C(O)ORA, and heterocyclealkyl. Examples of compounds of the present invention are those in which R9 is alkoxyalkyl, - C(O)ORA, and heterocyclealkyl, and RA is hydrogen, alkyl, aryl or arylalkyl. Other compounds included in the present invention are those in which Ri is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R2 is hydrogen, R3 is (Formula Removed) and R4 is -C(O)R8, wherein R8 is heterocycle or N(R8a)(R8b). Examples of compounds of the present invention are those in which R8 is heterocycle. Other compounds included in the present invention are those in which R1 is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R2 is heterocyclealkyl, R3 is (Formula Removed) and R4 is hydrogen. Examples of the present invention comprise compounds in which the heterocycle moiety of the heterocyclealkyl is unsubstituted. However, compounds in which the heterocycle moiety of the heterocyclealkyl is substituted with 1,2, 3 or 4 substituents selected from the group consisting of alkyl, -alkyl-ORB, and -alkyl-N(RB)2, are also comprised in the present invention. Other compounds included in the present invention are those in which Ri is alkyl, cycloalkyl, halogen or haloalkyL R2 is heterocyclealkyl, R3 is (Formula Removed) , and R4 is hydrogen. Compounds of the present invention include those wherein R1 is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R2 is hydrogen, R3 is (Formula Removed) , and R4 is -C(O)-O-(CH2)mR5, wherein R5 is selected from the group consisting of-0-P-O-(ORA)(ORA), -P(O)(ORA)(ORA), -ORA, -OC(O)(RA), heterocycle, -C(O)ORA, -C(O)N(RB)2, -C(O)(RA), and -N(RB)C(O)ORA. Examples of these compounds include those in which R5 is -0-P-O-(ORA)(ORA), and RA is independently selected from the group consisting of hydrogen, alkyl, aryl or arylalkyl. Other examples include those compounds in which R5 is -P-O-(ORA)(ORA), and RA is independently selected from the group consisting of hydrogen, alkyl, aryl or arylalkyl. Examples of compounds include those in which R5 is ORA and RA is independently selected from the group consisting of hydrogen, alkyl, aryl or arylalkyl. Other examples include those in which R5 is heterocycle. Examples include compounds in which R5 is OC(O)(RA), and RA is independently selected from the group consisting of hydrogen, alkyl, aryl or arylalkyl. Other examples include those compounds in which R5 is -C(O)ORA, and RA is independently selected from the group consisting of hydrogen, alkyl, aryl or arylalkyl. Other compounds included in the examples of the present invention are those in which R5 is -C-O-N(RB)2, and RB is selected between hydrogen and alkyl. Other compounds included in the examples of the present invention are those in which R5 is -N(RB)C(O)ORA wherein RB is selected between hydrogen and alkyl, and RA is independently selected from the group consisting of hydrogen, alkyl, aryl or arylalkyl. Other compounds of the present invention are those in which R1 is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R2 is hydrogen, R3 is (Formula Removed) and R4 is -C-O-R8, in which R8 is heterocycle or N(O)(R8b) wherein R8a and R8b are independently hydrogen or alkyl. Examples of the present invention include compounds in which R8 is heterocycle. Other compounds of the present invention are those in which R1 is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R2 is hydrogen, R3 is (Formula Removed) (b) and R4 is -CH2C(H)(OH)R9, wherein R9 is selected from the group consisting of alkoxyalkyl, -C-O-ORA, -alkyl-N(RB)C-O-ORA, and heterocyclealkyl. Examples of the present invention include compounds in which R9 is alkoxyalkyl. Other examples include compounds in which R9 is -C-O-ORA and RA is alkyl. Other examples include compounds in which R8 is heterocyclealkyl. Other compounds of the present invention include compounds in which R1 is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R1 is hydrogen, R3 is (Formula Removed) and R4 is -C-O--0-(CH2)mR5- Other compounds included in the invention are those in which, Ri is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R2 is hydrogen, R3 is (Formula Removed) and R4 is --C-O-(CH2)n-R6. Other compounds included in the invention are those in which, R1 is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R2 is hydrogen, R3 is (Formula Removed) andR4 is and-(CH2)r-R7- Other compounds included in the present invention have R1 is alkyl or alkenyl, preferably alkyl, R2 is heterocyclealkyl, R3 is (Formula Removed) and R4 is hydrogen. Furthermore, compounds of formula (IT) are considered within the scope of the present invention, (Formula Removed) wherein R1, R2, R3 and t are defined in compounds of formula (I). Other compounds of the present invention include compounds of formula (III) (Formula Removed) wherein R1, R2, R3 and t are defined in compounds of formula -O-. Other compounds of the present invention include compounds of formula (TV) (Formula Removed) (IV), wherein R1, R2, R3 and t are defined in compounds of formula (I). Other compounds of the present invention include compounds of formula (V) (Formula Removed) (V), wherein R1, R2, R3 and t are defined in compounds of formula (I). The following compounds are contemplated to be within the scope of the present invention: (Formula Removed) It is contemplated that any of the embodiments described above maybe combined and the scope of the compounds of the present invention defined under formula (I) is described by any such combinations. Compounds and compositions of the invention are useful for modulating the effects of vanilloid receptor activity, and more particularly the receptor type TRPVl. hi particular, the compounds and compositions of the invention can be used for treating and preventing disorders modulated by TRPVl. Typically, such disorders can be ameliorated by selectively modulating the TRPVl receptor in a mammal, preferably by administering a compound or composition of the invention, either alone or in combination with another active agent, for example, as part of a therapeutic regimen. The compounds of the invention, including but not limited to those specified in the examples, possess an affinity for TRPVl's. As TRPVl ligands, the compounds of the invention can be useful for the treatment and prevention of a number of diseases or conditions mediated by the TRPVl activity. For example, TRPVl have been shown to play a significant role in the release of inflammatory peptides such as, but not limited to, substance P and CGRP, leading to enhanced peripheral sensitization of tissue. As such, TRPVl ligands are suitable for the treatment of disorders associated with pain and inflammation. Further, capsazepine, a capsaicin receptor antagonist can reduce inflammation-induced hyperalgesia in animal models. TRPV1 receptors are also localized on sensory afferents, which innervate the bladder. Capsaicin or resiniferatoxin has been shown to ameliorate incontinence symptoms upon injection into the bladder. Therefore, TRPV1 ligands are suitable for the treatment of disorders associated with urinary incontinence and bladder dysfunction. Definition of Terms. As used throughout this specification and the appended claims, the following terms have the following meanings: The term "alkenyl" as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl,! 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl. The term "alkoxy" as used herein, means an alkyl group, as defined herein, appended , to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy. The term "alkoxyalkyl" as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl, and methoxymethyl. The term "alkyl" as used herein, means a straight or branched chain, hydrocarbon containing from 1 to 10 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n- f pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. The term "aryl" as used herein, means phenyl or a bicyclic aryl. The bicyclic aryl is naphthyl, or a phenyl fused to a monocyclic cycloalkyl, or a phenyl fused to a monocyclic cycloalkenyl. The phenyl and the bicyclic aryl groups of the present invention are unsubstituted or substituted. The bicyclic aryl is attached to the parent molecular moiety through any carbon atom contained within the bicyclic aryl. Representative examples of the aryl groups include, but are not limited to, dihydroindenyl, indenyl, naphthyl, dihydronaphthalenyl, 1,3-benzodioxolyl, 2,3-dihydro-l,4-benzodioxin-6-yl, and 5,6,7,8- tetrahydronaphthalenyl. The term "arylalkyl" as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and 2-naphth-2-ylethyl. The term "halo" or "halogen" as used herein, means -CL -Br, -I or -F. The term "haloalkoxy" as used herein, means an alkoxy group as defined herein, wherein one to six hydrogen atoms are replaced by halogens. Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2-fluoroethoxy, trifluoromethoxy, 2-chloro-3-fluoropentyloxy, and pentafluoroethoxy. The term "haloalkyl" as used herein, means an alkyl group as defined herein, wherein one to six hydrogen atoms are replaced by halogens. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fiuoropentyl. The term "heterocycle" or "heterocyclic" as used herein, means a monocyclic three-, four-, five-, six-, seven- or eight-membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S. The three- or four-membered ring contains zero or one double bond, and one heteroatom selected from the group consisting of O, N and S. The five-membered ring contains zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S. The six-membered ring contains zero, one or two double bonds and one, two or three heteroatoms selected from the group consisting of O, N and S. The seven-membered ring contains zero, one, two, or three double bonds and one, two or three heteroatoms selected from the group consisting of O, N and S. The monocyclic heterocycle is unsubstituted or substituted and is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle. Representative examples of monocyclic heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, l,3-dioxolan-4-yl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. The term "heterocyclealkyl" as used herein, means a heterocycle group, as defined herein, appended to the parent moiety through an alkyl group, as defined herein. Examples of heterocyclealkyl of the present invention include, but not limited to, 2-morpholin-4-yl-ethyl and 2-piperidin-l-yl-ethyl. The term "hydroxy" as used herein, means an -OH group. The term "hydroxyalkyl" as used herein, means at least one hydroxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4rhydroxyheptyl. The term "oxo" as used herein, means =0. Compounds of the present invention may exist as stereoisomers wherein, asymmetric or chiral centers are present. These stereoisomers are "R" or "S" depending on the configuration of substituents around the chiral carbon atom. The terms "R" and "S" used herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem., 1976,45: 13-30. The present invention contemplates various stereoisomers and mixtures thereof and these are specifically included within the scope of this invention. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the present invention may be prepared synthetically from commercially available starting materials that contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution which is well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns, or fractional recrystalization of salt of the compounds of the present invention with chrial carboxylic acids followed by neutralization to obtain the pure steroisomer of the compound of the present invention. The compounds and processes of the present invention will be better understood by reference to the following Examples, which are intended as an illustration of and not a limitation upon the scope of the invention. Further, all citations herein are incorporated by reference. Compounds of the invention were named by ACD/ChemSketch version 5.01 (developed by Advanced Chemistry Development, Inc., Toronto, ON, Canada) or were given names consistent with ACD nomenclature. Alternatively, compounds were assigned names using ChemDraw Ultra 9.0 (or higher version) (Cambridgesoft). The practice of assigning names to chemical compounds from structures, and of assigning chemical structures from given chemical names is well known to those of ordinary skill in the art. Preparation of Compounds of the Present Invention The compounds of this invention can be prepared by a variety of synthetic procedures. Representative procedures are shown in, but are not limited to, Schemes 1-11. Scheme 1 (Scheme Removed) As outlined in Scheme 1, ketone containing compounds of formula (3) may be converted into compounds of formula (8) which are used in the synthesis of compounds of formula (I). Compounds of formula (3) when heated in the presence of a compound of formula (4) or similar chiral amine containing compound in toluene under Dean-Stark conditions with or without a catalytic amount of acid, followed by treatement with reducing conditions such as but not limited to sodium borohydride in ethanol will provide a compounds of formula (5). Compounds of formula (5) when treated with an atmosphere of hydrogen in the presence of a palladium catalyst such as palladium on carbon in solvents such as but not limited to methanol or ethanol with our without a catalytic amount of an acid such as acetic acid will provide compounds of formula (8) wherein Ri is as defined in formula (I). Alternatively, compounds of formula (3) when treated with an hydroxylamine or O-substituted hydroxyl'amines such as, but not limited to memoxyamine, in the presence of a solvent such as, but not limited to, pyridine or mixtures of ethanol and pyridine at a temperature from about room temperature to about 50 °C will provide oximes of formula (6). Oximes of formula (6) can be reduced in the presence of an atmosphere of hydrogen gas from about 40 to about 60 psi and a catalyst such as, but not limited to palladium on carbon at a temperature from about 50 °C to about 70 °C to provide compounds of formula (7). Compounds of formula (7) made through this method exist as a mixture of enantiomers that may be resolved by fractional crystallization when converted to salt with chiral carboxylic acid. Chiral carboxylic acids useful in forming salts with compounds of formula (7) include chiral amino acids such as, but not limited to, N-acetyl-(D)-leucine and N-tert-butyloxycarbonyl phenylalanine. The fractional crystallization of compounds of formula (7) with chiral carboxylic acids will provide after neutralization the individual isomers of (R) or the (S) form of the amine of formula (8). Scheme 2 (Scheme Removed) will produce racemic mixtures of compounds of formula (13) and racemic mixtures of compounds of formula (14). Alternatively, compounds of formula (10) can be treated with phosgene or triphosgene and 4-dimemylaminopyridine in a solvent such as, but not limited to, dichloromethane, followed by treatment with amines of general formula (9) in a solvent such as, but not limited to, toluene or tetrahydrofuran or a combination thereof to provide ureas of general formula (13) wherein Ra is hydrogen or heterocyclealkyl. It is also known to one skilled in the art that compounds of formula (10) can be treated with trichloroacetyl chloride and a base such as, but not limited to, triethylamine in a solvent such as dichloromethane to provide trichloroacetamides, which in turn can be treated with amines of formula (9) and a non-nucleophilic base such as, but not limited to, 1,8-diazabicyclo[5.4.0]undec-7-ene in a solvent such as, but not limited to, acetonitrile, to provide ureas of general formula (13) wherein R.2 is hydrogen or heterocyclealkyl. Compounds of formula (9) wherein R2 is heterocyclealkyl can be obtained from amines of formula (8) by treatment with halides of formula R2X wherein X is CI, Br or I, in the presence of a base such as but not limited to sodium carbonate or potassium carbonate, optioanally in the presence of catalytic amount of tetrabutylammonium iodide. The reaction is generally performed in solvents such as but not limited to N,N-dimethylformamide, methanol, ethanol, and mixtures thereof. Compounds of formula (13) wherein R2 is heterocyclealkyl can also be prepared from compounds of formula (13) wherein R2 is hydrogen employing the reaction conditions for the transformation of compounds of formula (8) to compounds of formula (9). Scheme 3 (Scheme Removed) Compounds of formula (16) and (17) wherein r, Riand R7 are as defined in formula (1) can be obtained from compounds of formula (15) by treatment with halides of formula R.7(CH2)rX, wherein X is CI, Br or I, in the presence of a base such as but not limited to potassium carbonate, sodium carbonate or sodium hydride, and optionally in the presence of tetrabutyl ammonium iodide. The reaction is generally conducted in a solvent such as, but not limited to N,N-dimeuiylformamide, and at a temperature from about room temperature to about 100 °C. The two regioisomers obtained can be separated using purification techniques such as but not limited to column chromatography on silica gel. The compounds of formula (15), (16) and (17) are drawn to represent chiral compounds in this Scheme are for clarity purposes only. The same synmetic strategy may be carried out with the racemic compound of formula (15), which will produce the racemic mixtures of compounds of formula (16) and of formula (17). Similarly, the following schemes also are depicting using a chiral starting material but alternatively when carried out using a racemic mixture of a starting material or the opposite enantiomer will produce a racemic mixture of products or the opposite enantiomeric product, respectively. Scheme 4 (Scheme Removed) Compounds of formula (18) wherein n, Ri and R^ are as defined in formula (1) can be synthesized as outlined in Scheme 4. Acyl chlorides of formula R6(CH2)nCOCl, or anhydrides such as, but not limited to, glutaric anhydride, succinic anhydride or acetic anhydride, purchased or prepared using methodologies known to one skilled in the art, and an amine such as, but not limited to triemylamine, pyridine or mixture thereof, when treated with imidazoles of formula (15), provides compounds of formula (18). The reaction can be conducted with or without a solvent at about room temperature, for a period of about 1 hour to about 5 days. Example of a solvent that can be employed includes, but not limited to, tetrahydrofuran. Scheme 5 (Scheme Removed) Alternatively, compounds of formula (18) can also be obtained from compounds of formula (15) by treatment with acids of formula R$(CH2)nCOOH, purchased or prepared by known methodologies, in the presence of a coupling agent such as, but not limited to, N,N'-dicyclohexylcarbodiimide. The reaction can be conducted at ambient temperature and in a solvent such as, but not limited to, dichloromethane, tetrahydrofuran, N,N-dimethylformamide, or mixture thereof. Compounds of formula (15) can be transformed to compounds of formula (19) and (20) wherein R1 and Rg are as defined in formula (1) as shown in Scheme 5. Treatment of compounds of formula (15) and carbonyl chlorides of formula R8COCl wherein R8is either N-O-(R8b) or a heterocycle wherein the ring nitrogen atom is attached to the carbonyl moiety of the carbonyl chloride, followed by separation of the two regioisomers employing known purification technique such as but not limited to column / chromatograph on silica gel, furnished compounds of formula (19) or (20). The reaction can be performed in a solvent such as but not limited to N.N-dimethylformamide, and in the presence of abase such as but not limited to sodium hydride. Treatment of compounds of formula (15) with carbonyl chlorides of formula RgCOCl wherein the carbonyl moiety is appended to Ihe carbon atom of the heterocycle ring afford compounds of formula (19) under the forgoing reaction conditions. Carbonyl chlorides of formula RgCOCl can be purchased or prepared from acids of formula RgCOOH with thionyl chloride in the presence of catalytic amount of N,N-dimethylformamide, at a temperature of about room temperature, in a solvent such as, but not limited to, dichloromethane. Scheme 6 (Scheme Removed) Compounds of formula (24) wherein R1, R5 and m are as defined in formula (I) can be prepared as outlined in Scheme 6. Compounds of formula (15) when treated with compounds of formula (21) or (23) and a base such as but not limited to potassium tert-butoxide, in a solvent such as, but not limited to, N,N-dimethylformamide, at a temperature from about 0 °C to about room temperature, provides compounds of formula (24). Alternatively, compounds of formula (24) can be obtained by treating compounds of formula (15) with chloroformates of formula R5(CH2)mOC-O-Cl (purchased or prepared by known methodologies) in the presence of a base such as but not limited to 4-methylmorpholine, in a solvent such as, but not limited to, tetrahydrofuran. Compounds of formula (21) or (23) can be prepared from alcohols of formula (20), by treatment with 4-nitrophenyl chloroformate or carbonate of formula (22) respectively, in the presence of a base such as, but not limited to, triethylamine or pyridine, in a solvent such as, but not limited to, dichloromethane or acetonitrile. Scheme 7 (Scheme Removed) Compounds of formula (25) or (26) wherein R1 and R9 are as defined in formula -O-, can be prepared from compounds of formula (15), by treatment with substituted oxiranes (prepared by known methodologies or purchased) and a base such as, but not limited to, sodium tert-butoxide, sodium carbonate or potassium carbonate. The two regioisomers obtained can be separated by column chromatography or other purification techniques known to one skilled in the art. The reaction can be conducted at an elevated temperature from about 70 °C to about 120 °C, in a solvent such as, but not limited to, methanol, ethanol, or acetonitrile. It is understood that Schemes 2-7 depicting chiral compounds is done only for illustrative purposes only, and that the use of a racemic mixture of one starting material or the opposite enantiomer will produce a racemic mixture of products or the opposite enantiomeric product, respectively. Scheme 8 (Scheme Removed) More specifically, compounds of the present invention which contain an amino-indane moiety may be prepared as outlined in Scheme 8. For example, chloropropionyl chloride when treated with aluminum chloride in a solvent such as but not limited to methylene chloride followed by the addition of a compound of formula (28) will provide a compound of formula (29). Compounds of formula (29) when treated with concentrated sulfuric acid or poly phosphoric acid followed by heating will provide compounds of formula (30). Compounds of formula (30) when treated according to the procedure outlined in Scheme 1 will provide amines of formula (31). Furthermore compounds of formula (31) when treated according to the procedures outlined in Scheme 2 will provide compounds of formula (32). Compounds of formula (32) when treated according to the procedures outlined in Scheme 3-5 will provide compounds of formula (33) which are representative of compounds of the present invention. Scheme 9 (Scheme Removed) As outlined in Scheme 9, compounds of formula (34) when treated with a ketone substituted with R11, wherein each occurance of R11 are independently hydrogen, alkyl or aryl, or two R11 groups that are attached to a single carbon atom or two adjacent carbon atoms together form a cycloalkyl ring; and a base such as but not limited to pyrrolidine in a solvent such as but not limited to toluene heated to reflux containing a Dean-Stark trap will provide compounds of formula (35). Compounds of formula (35) when treated according to the procedures outlined in Schemes 1-5 will provide compounds of formula (33), which are representative of compounds of the present invention. Scheme 10 (Scheme Removed) As shown in Scheme 10, compounds of formula (37), wherein R1 and t are defined in formula(I) when treated with propargyl bromide in the presence of a base such as but not limited to potassium carbonate in a solvent such as but not limited to acetonitrile will provide compounds of formula (39). Compounds of formula (39) when treated with N-chlorosuccinimide and silver acetate in a solvent such as but not limited to acetone with heating will provide compounds of formula (40). Compounds of formula (40) when treated with ethylene glycol at reflux will provide compounds of formula (41). Compounds of formula (41) when treated according to the procedures outlined in Schemes 1-5 will provide compounds of formula (42) Scheme 11 (Scheme Removed) As outlined in Scheme 11, compounds of formula (43) wherein R1 and t are defined in formula (I), when treated with a base such as cesium carbonate in acetonitrile or sodium hydride in DMF followed by the treatment with methyl 3-bromopropionate will provide compounds of formula (44). Compounds of formula (44) when treated with sodium, lithium or potassium hydroxide in an aqueous alcoholic solvent will provide compounds of formula (45). Compounds of formula (45) when heated in the presence of polyphosphoric acid will provide compounds of formula (46). Compounds of formula (46) when treated according to conditions outlined in Schemes 1-5 will provide compounds of formula (47), which are representative of compounds of the present invention. It is understoond that the schemes described herein are for illustrative purposes and that routine experimentation, including appropriate manipulation of the sequence of the synthetic route, protection of any chemical functionality that are not compatible with the reaction conditions and the removal of such protecting groups are included in the scope of the invention. It is understood that Schemes 8-11 depicting racemic mixtures of compounds is done only for illustrative purposes only, and that the use of a single enantiomeric starting material will produce a single enantiomeric product. The following Examples are intended as an illustration of and not a limitation upon the scope of the invention as defined in the appended claims. Example 2 N-[(lR)-S-tertbutyl-2,3-dihyd-lH-l-yl]-(2-morphoin-4- 4-yl]urea To a solution of compound from Example 56J (150 mg, 0.43 mmol) in 2 ml dimethylformamide was added potassium carbonate (180 mg, 1.3 mmol) and 4-(2-chloro-ethyl)-morpholine hydrochloride (121 mg, 0.65 mmol). The reaction was stirred for eleven days at ambient temperature. At this point, a catalytic amount (10 mg) of tetrabutylammonium iodide was added, and the reaction continued for 16 hours longer. The reaction mixture was diluted with water and filtered. The filtercake was then purified by chromatography on silica gel, using 5% ethanol/ethyl acetate as solvent, to give 92 mg of the title compound. 'HNMR (300 MHz, DMSO-d6) 8 ppm 8.56 (s, 1 H), 8.02 (s, 1 H), 7.70 (d, J=7.12 Hz, 1 H), 7.17 - 7.32 (m, 5 H), 6.68 (d, J=7.80 Hz, 1 H), 5.15 (m, 1 H), 4.46 (t, J=6.61 Hz, 2 H), 3.44 - 3.53 (m, 4 H), 2.87 - 2.79 (m, 4 H), 2.38 - 2.52 (m, 5 H), 1.76 -1.90 (m, 1 H), 1.28 (s, 9 H). MS (ESI) m/e 462 (M+H)+. Calcd. For C27H35N5O2-O^O: C 69.17, H 7.70, tf 14.94; Found C 69.39, H 7.78, N 14.95. Example 3 2- {4-[( {[(1R)-5-te^butyl-2,3-dmyfao-12f-mden4-yl]am^ yl}-2-oxoethyl acetate To a solution of compound from Example 56J (1.05 g, 3 mmol) in 10 ml pyridine and 1.5 ml triethylamine was added acetoxyacetyl chloride (0.54 ml, 0.68 g, 5 mmol). The reaction was stirred at ambient temperature for four days and the solvent was removed under reduced pressure. The residue was purified twice by chromatography on silica geL using 25% to 40% ethyl acetate/hexane, to give 0.26g of the title compound. JH NMR (300 MHz, DMSO-ds) S. ppm 8.46 (s, 1 H) 8.90 (s, 1 H), 7.91 (d, J=7.80 Hz, 1 H), 7.80 (d, J=8.14 Hz, 1 H), 7.54 (t, J=8.14 Hz, 1 H), 7.25 - 7.37 (m, 3 H), 6.71 (d, J=8.14 Hz, 1 H), 5.49 (s, 2 H), 5.17 (m, 1 H), 2.89 - 3.10 (m, 1 H), 2.74 - 2.88 (m, 1 H), 2.36 - 2.52 (m, 1 H), 2.19 (s, 3 H), 1.71 -1.96 (m, 1 H), 1.27 (s, 9 H). MS (ESI) m/e 489 (M+H)+. Calcd. For C25H2gN404: C 66.95, H 6.29, N 12.49; Found C 66.74, H 6.43, N 12.28. Example 4 me%14-({[[(l/?)-5-tert-butyl-2,3-dmydro4JY-inden-l-yl](2-morpholin-4- ylethyl)amino]carbonyl} amino)- l#-indazole-l-carboxylate Example 4A N-[(1R)-5-fe^butyl-2,3-dmydro-l#-in^^ 4-(2-Chloro-ethyl)-morpholine hydrochloride (0.56g, 3mmol), compound from Example 56K (1.08g, 3 mmol), and sodium carbonate (1.06g, 10 mmol) were suspended in 5 ml of ethanol and heated to reflux for four hours. The reaction mixture was then cooled, stirred for two days at ambient temperature, and diluted with water. The aqueous solution was extracted with diethyl ether, and the combined organic layers were dried with magnesium sulfate. The solvent was removed under vacuum to give 0.85g crude title compound as an oil that was used without further purification. Example 4B me%14<{[[(1R)-5-^^utyl-2,3-dmydro4^-mden4-yl](2-morpholin-4-ylemyl)amino]carbonyl} amino)- 1/f-indazole-1 -carboxylate Step A The product of Example 56C (1.9 g, 10 mmol) and disuccinimidylcarbonate (2.8 g, 11 mmol) in acetonitrile (100 mL) was stirred for 48 hours under nitrogen atmosphere. The solid was isolated by filtration, washed with acetonitrile (10 mL) and dried under vacuum at ambient temperature to give an off-white solid (2.56 g, 77%). StepB: Example 4A (0.85 g 2.8 mmol) and intermediate from Step A of Example 4B (0.66 g, 2 mmol) were dissolved in 5 ml dimethylformamide, and dusoprbpylemylarnine (0.39g, 0.52 ml, 3 mmol). The reaction was stirred at ambient temperature for 16 hours, then diluted with water and filtered. The solid collected was purified via flash chromatography using a gradient of 35% to 50% ethyl acetate in hexanes. After evaporation of solvent, the purified product was further dried by the addition of toluene followed by evaporation under vacuum, giving 0.70g of title compound. lH NMR (300 MHz, DMSO-dg) 5 ppm 8.27 (s, 1 H), 7.83 (d, J=8.48 Hz, 1 H), 7.55 (t, J=8.14 Hz, 1 H), 7.37 (d, J=7.46 Hz, 1 H), 7.11 - 7.33 (m, 4 H), 5.76 (t, J=7.97 Hz, 1 H), 4.04 (s, 3 H),3.47 - 3.51 (m, 4 H), 3.11 - 3.42 (m, 4 H), 2.96 - 3.02 (m, 1 H), 2.71 - 2.89 (m, 1 H), 2.33-2.47 (m, 5 H), 2.30 (s, toluene, 1.2 H), 1.89 - 2.14 (m, 1 H), 1.29 (s, 9 H). MS (ESI) m/e 520 (M+H)+. Calcd. For C29H37NsO4.0.4toluene-0.3H2O: C 67.97, H 7.32, N 12.46; Found C 68.07, H 7.05, N 12.41. 5 Example 5 AK(l/0-5-fer^butyl-2,3-dmydro-l#-mden^ ylethyl)urea Example 4B (0.49g, 0.94 mmol) was dissolved in a minimum amount of methanol. 1. 10 ml of 5M sodium hydroxide in methanol was added, and the reaction stirred at ambient temperature for one hour. The reaction mixture was then diluted with water, and the product collected by filtration. Tituration with diethyl ether followed by drying under vacuum gave 0.35g of the title compound. !H NMR (300 MHz, DMSO-de) $ ppm 12.94 (s, 1 H), 9.38 (s, 1 H), 7.80 (s, 1 H), 6.83 - 7.53 (m, 6 H), 5.73 (t, J=7.97 Hz, 1 H), 3.48 - 3.51 (m, 4 H), 3.38 - 15 3.48 (m, 1H), 3.18 - 3.24 (m, 1H), 2.96 - 3.01 (m, 1H), 2.80 - 2.86 (m, 1H), 2.40 - 2.56(m, 7H), 1.96 - 2.03 (m, 1H), 1.30 (s5 9 H). MS (ESI) m/e 462 (M+H)+. Calcd. For C27H35N5O2»0.3tetrahyarofuran»0.1H2O: C 69.74, H 7.93, N 14.42; Found C 69.70, H 7.73, N 14.30. 20 Example 6 ^-{l-[(benzyloxy)acetyl]-l^-mdazol-4-yl}-7^-[(1R)-5-te^butyl-2,3-a^ydro-li7-inden-l- yl]urea To a solution of compound from Example 56J (1.05 g, 3 mmol) in 10 ml pyridine and 1.5 ml triemylamine was added benzyloxy-acetyl chloride (1 ml, 1.11 g, 6 mmol). The 25 reaction was stirred at ambient temperature for three days and the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate, washed with water, the organic layer dried with magnesium sulfate, and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel, using 2% methanol in methylene chloride, then titurated with 1:1 ether:hexanes, to give 1.19 g of the title compound. *H NMR 30 (300 MHz, DMSO-de) § ppm 8.86 (s, 1 H), 8.39 (s, 1 H), 7.86 - 7.94 (m, 2 H), 7.54 (t, J=8.14 Hz, 1 H), 7.30 - 7.45 (m, 6 H), 7.27 (s, 2 H), 6.70 (d, J=7.80 Hz, 1 H), 5.16 (m, 1 H), 5.02 (s, 2 H), 4.71 (s, 2 H), 2.91 - 3.01 (m, 1 H), 2.77 - 2.88 (m, 1 H), 2.41 - 2.49 (m, 1 H), 1.85 (dd, J=12.55, 7.80 Hz, 1 H), 1.28 (s, 9 H). MS (ESI) m/e 497 (M+H)+. Calcd. For C30H32N4O3: C 72.56, H 6.49, N 11.28; Found C 72.42, H 6.52, N 11.02. Example 7 JV"-[(l£)-5-fer^butyl-2,3-dmycl^ The title compound was prepared using the procedure as described in Example 6, substituting methyloxy-acetyl chloride for benzyloxy-acetyl chloride. !H NMR (300 MHz, DMSO-d6) § ppm 8.86 (s, 1 H), 8.40 (s, 1 H), 7.88 (dd, J=10.51, 8.14 Hz, 2 H), 7.53 (t, J=8.14 Hz, 1 H), 7.24 - 7.32 (m, 3 H), 6.70 (d, J=7.80 Hz, 1 H), 5.16 (q, J=7.23 Hz, 1 H), 4.90 (s, 2 H), 3.45 (s, 3 H), 2.96 (m, 1 H), 2.82 (m, 1 H), 2.41 - 2.48 (m, 1 H), 1.79 - 1.91 (m, 1 H), 1.28 (s, 9 H). MS (ESI) m/e 421 (M+H)+. Calcd. For C24H28N4O3»0.2H2O: C 67.97, H 6.75, N 13,21; Found C 68.03, H 6.68, N 13.13. Example 8 4-{4-[({[(li2)-5-ter^butyl-2,3-dmydro-l^-mden-l-yl]animo}carbonyl)ammo]-lJ7-indazol-l- yl}-4-oxobutanoic acid To a solution of Example 56J (2.09 g, 6 mmol) in 50 ml tetrahydrofuran and 6 ml triethylamine was added succinic anyhdride (1.20 g 12 mmol). The reaction was stirred 7 days at ambient temperature, then diluted with water and ethyl acetate, made acidic with IN aqueous HC1, and extracted with ethyl acetate. The combined organic layers were dried with magnesium sulfate and the solvent removed under reduced pressure to give 2.95g of the title compound. ]H NMR (300 MHz, DMSO-de) 5. ppm 12.21 (s, 1 H), 8.87 (s, 1 H), 8.42 (s, 1 H), 7.88 (m, 2 H), 7.50 (t, J=8.14 Hz, 1 H), 7.04 - 7.37 (m, 3 H), 6.72 (d, J=7.80 Hz, 1 H), 5.17 (m, 1 H), 4.03 (q, Ethyl acetate), 3.37 - 3.42 (m, 2 H), 2.89 - 3.06 (m, 1 H), 2.75 - 2.89 (m, 1 H), 2.67 - 2.71 (m, 2 H), 2.33 - 2.46 (m, 1 H), 1.99 (t, Ethyl acetate), 1.67 -1.95 (m, 1 H), 1.28 (s, 9 H), 1.17 (t, Ethyl acetate). MS (ESI) m/e 449 (M+H)+. Calcd. For C25H28N4O4«0.4ethyl acetate* 1.2H20: C 63.22, H 6.70, N 11.09; Found C 63.06, H 6.26, N 10.94. Example 9 W-[(l£)-5-tert-butyl-2,3-dihy^ yl]urea, trifluoroacetic acid salt To a solution of Example 56 J (3.48 g, 10 mmol) in 33 ml pyridine and 10 ml triethylamine was added dimethylamino-acetyl chloride hydrochloride (4.74 g, 30 mmol). The reaction was stirred at ambient temperature for two days and the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate, washed with water and saturated aqueous sodium bicarbonate, the organic layer dried with magnesium sulfate, and the solvent removed under reduced pressure. The crude product obtained was purified using reverse-phase HPLC (acetonitrile-water with 0.1% trifluoroacetic acid as eleuent) to give the title compound. lH NMR (300 MHz, DMSO-d6) § ppm 8.98 (s, 1 H), 8.54 (s, 1 H), 7.85 -7.92 (m, 2 H), 7.60 (t, J=8.14 Hz, 1 H), 7.26 - 7.33 (m, 3 B), 6.75 (d, J=7.80 Hz, 1 H), 5.17 (m, 1 H), 4.99 (s, 2 H), 3.23 - 3.37 (s, 1H, under H20), 2.96 (s, 6 H), 2.91 - 3.01 (m, 1 H), 2.77 - 2.88 (m, 1H), 1.82 - 1.91 (m, 1 H), 1.28 (s, 9 H). MS (ESI) m/e 434 (M+H)+. Calcd. For C25H3iN502«1.2trifluoroacetic acid: C 57.70, H 5.69, N 12.28; Found C 57.63, H 5.51, N 12.27. Example 10 iV-[(1R)-5-rer^utyl-2,3-dmydro-lH-mden-l-yl]-iV,-(l-glycoloyl-li7-indazol-4-yl)urea Example 6 (1.06g, 2.1 mmol) was dissolved in 10 ml tetrahydrofuran and was then subjected to hydrogenolysis over palladium hydroxide (1.10g of 20% Pd(OH)2 on carbon, wet). The reaction was stirred at ambient temperature for 16 hours under a 50 psi hydrogen atmosphere. Filtration and removal of solvent under vacuum gave 0.54 g of title compound. lB NMR (300 MHz, DMSO-dg) 5 ppm 8.85 (s, 1 H), 8.39 (s, 1 H), 7.88 (t, J=7.80 Hz, 2 H), 7.52 (t, J=8.14 Hz, 1 H), 7.25 - 7.37 (m, 3 H), 6.70 (d, J=7.80 Hz, 1 H), 5.43 (t, J=6.44 Hz, 1 H), 5.16 (q, J=7.35 Hz, 1 H), 4.87 (d, J=6.44 Hz, 2 H), 2.66 - 3.07 (m, 2 H), 2.35 - 2.48 (m, 1 H), 1.78 - 1.94 (m, 1 H), 1.22 - 1.32 (m, 9 H). MS (ESI) m/e 407 (M+H)+ Example 11 A4(l.R)-5-ter^butyl-2,3-dmydro4i^ ylethyl)urea 5 Example 11A ((R)-5-tert-Butyl-indan-1 -yl)-(2-piperidin-1 -yl-ethyl)-amine The title compound was prepared using the procedure as described in Example 4A, substituting l-(2-chloro-ethyl)-piperidine hydrochloride for 4-(2-chloro-ethyl)-morpholine 10 hydrochloride. The crude compound was used without further purification. Example 1 IB' memyl4-({[[(1R)-5-te^butyl-2,3-o^ydro-liy-inden-l-yl](2-piperidin-l- ylethyl)amino] carbonyl} amino)- li7-indazole-1 -carboxylate 15 The title compound was prepared using the procedure as described in Example 4B, substituting Example 11A for Example 4A. The crude product was purified using reverse- phase HPLC (acetonitrile-water with 0.1% trifluoroacetic acid as eleuent) to give 0.32 g of the desired compound. lR NMR (300 MHz, DMSO-ds) $ ppm 9.16 (s, 1 H), 8.97 (s, 1 H), 8.34 (s, 1 H), 7.86 (d, J=8.48 Hz, 1 H), 7.46 - 7.65 (m, 1 H), 7.30 - 7.42 (m, 2 H), 7.23 (d, 20 J=7.80 Hz, 1 H), 5.73 (t, J=7.80 Hz, 1 H), 4.04 (s, 3 H), 2.65 - 3.89 (m, 11 H), 2.49 - 2.65 (m, 1 H), 1.30 - 1.89 (m, 6 H), 1.30 (s, 9 H). MS (ESI) m/e 518 (M+H)+. Example 11C N-[(lR)-5-tert-butyl-2,3-dmydro-lH-mden-l-yl]-N1-lH-mdazol-4-yl-N-(2-piperidin-l- 25 ylethyl)urea The title compound was prepared using the procedure as described in Example 5, substituting Example 1 IB for Example 4B. 'H NMR (300 MHz, DMSO-de) 5 ppm 12.89 (br s, 1 H), 10.06 (br s, 1 H), 7.86 (s, 1 H), 7.03 - 7.41 (m, 6 H), 5.77 (t, J=7.97 Hz, 1 H), 3.25 - 3.44 (m, 2 H), 3.06 - 3.22 (m, 1 H), 2.89 - 3.05 (m, 1 H), 2.69 - 2.89 (m, 1 H), 2.32 - 2.48 (m, 30 6 H), 1.83 - 2.06 (m, 1 H), 1.30 - 1.57 (m, 6 H), 1.29 (s, 9 H). MS (ESI) m/e 460 (M+H)+. Calcd. For C28H37N5O»0.1H2C-0.33NaCl: C 69.96, H 7.80, N 14.57; Found C 69.90, H 7.80, N 14.37. Example 12 5- {4-[( {[Q.R)-5-tert-butyl-2,3-dihydro- l#rinden~1 -yl] amino} carbonyl)amino] - l#-indazol-1 - yl}-5-oxopentanoic acid To a solution of Example 56J (0.52 g, 1.5 mmol) in 7 ml tetrahydrofuran and 1.5 ml triethylamine was added glutaric anyhdride (0.34 g 3 mmol). The reaction was stirred 5 days at ambient temperature, then was diluted with water and ethyl acetate, made acidic with IN aqueous HC1, and extracted with ethyl acetate. The combined organic layers were dried with magnesium sulfate and the solvent removed under reduced pressure. The residue was found to contain a large amount of glutaric acid, which was removed by tituration with water to give 0.61 g of the title compound. !H NMR (300 MHz, DMSO-de) 8 ppm 12.10 (br s, 1 H), 8.85 (s, 1 H), 8.39 (s, 1 H), 7.90 (d, J=4.75 Hz, 1 H), 7.87 (d, J=5.42 Hz, 1 H), 7.50 (t, J=8.14 Hz, 1 H), 7.23 - 7.35 (m, 2 H), 6.71 (d, J=8.14 Hz, 1 H), 5.09 - 5.27 (m, 1 H), 3.15 - 3.27 (t, J=7.46 Hz, 2 H), 2.89 - 3.06 (m, 1 H), 2.73 - 2.89 (m, 1 H), 2.41 - 2.48 (m, 1 H), 2.37 (t, J=7.29 Hz, 2 H), 1.88 - 2.00 (m, 2 H), 1.77 - 1.89 (m, 1 H), 1.28 (s, 9 H). MS (ESI) m/e 463 (M+H)+. Calcd. For GaeHso^CVO^HzO: C 66.48, H 6.61, N 11.93; Found C 66.43, H 6.38, N 11.82. Example 13 2-(phosphonooxy)emyl4-[({[(li2)-5-te^butyl-2,3-dihydro-li/-inden-l-yl]ammo}carbonyl)amino]-l^-indazole-l-carboxylate To Example 14D (0.37 g, 0.6mmol) in a 250 ml round bottom flask was added acetonitrile (40 ml) and 0.1% trifluoroacetic acid in water (40 ml) and the reaction was stirred at room temperature for 4 days. Every 24 hours 0.5ml of trifluoroacetic acid was added. After four days, the reaction was concentrated to give a white powder in 84% yield. !H NMR (DMSO-d6,300MHz); 8 1.28 (s, 9H), 1.74-1.91 (m, 2H), 2.41-2.54 (m, 1H), 2.77-3.38 (m, 2H), 4.18-4.23 (m, 2H), 4.60-4.63 (m, 2H), 5.13-5.20 (m, 1H), 6.68 (d, J=7.8Hz, 1H), 7.24-7.28 (m, 2H), 7.50 (t, J=8.41,16.18Hz, 1H), 7.71 (d, J=8.48Hz, IE), 7.90 (d, J=8.27Hz, 1H), 8.41 (s, 1H), 8.84 (s, 1H). MS (DCI/NH3) m/z 517; Calc for C24H29N4O7P: C, 55.04; H, 5.74; N, 10.70. Found: C, 55.18; H, 5.50; N, 10.52. Example 14 2^(&-fert-butoxyphosphoryl)oxy]ethy^ yl]ammo}carbonyl)amino]-li?-indazole-l-carboxylate Example 14A Carbonic acid 2-benzyloxy-ethyl ester 4-nitro-phenyl ester To a 250ml round bottom flask was added 2-benzyloxyethanol (7.54 g, 49.60 mmol) (Aldrich), 4-nitrophenyl chloroformate (10 g, 49.60 mmol) (Aldrich), dichloromeihane (100 ml) followed by the addition of pyridine (5.89 g, 79.10 mmol) and the reaction was stirred at room temperature for 12 hours. The reaction was diluted with 200 ml of dichloromethane was washed with IN HC1 (100 ml), sat NaHC03 (100 ml), dried (Na2S04) and concentrated in vacuo. The reaction was purified on Si02 and eluted with hexane/ethyl acetate 4/1 to provide a yellow solid (11.20 g) in 71% yield. 'H NMR (CDC13, 300 MHz); 8 ppm 3.70-3.80 (m, 2H), 4.30-4.57 (m, 2H), 4.61 (s, 2H), 7.26-7.40 (m, 7H), 8.26 (d, J=8.82Hz, 2H); DCl/NHsm/z 318.00. Example 14B 2-(benzyloxy)ethyl 4-[({[(1R)-5-terf-butyl-2,3-dihydro-lfl"-inden-l-yl]arm^o}carbonyl)amino]-li?-mdazole-l-carboxylate To a 250 ml round bottom flask was added Example 56J (5.0 g, 14.40 mmol), anhydrous N,N-dimethylformamide (40 ml) and 1M in tetrahydrofuran potassium tert-butoxide (17.30 ml) and the reaction was stirred at room temperature for 1 hour. To the reaction mixture was added Example 14A (5.50 g, 17.70 mmol) at 0°C and the reaction was stirred for 12 hours while allowing to warm to room temperature. The reaction was poured into a separatory funnel and extracted with ethyl acetate (200 ml) and washed with EfeO (100 ml), brine (100 ml), dried (Na2SC>4) and concentrated in vacuo. The mixture was purified on Si02 eluting with hexane/ethyl acetate 1/1 to provide a white solid (6.78 g) in 74% yield. *H NMR (DMSO-de, 300MHz); 8 ppml.27 (s, 9H), 1.74-1.84 (m, 1H), 2.50-2.60 (m, 1H), 2.73-2.93 (m, 3H), 3.61 (t, J=4.41, 9.16Hz, 2H), 3.75-3.82 (m, 4H), 5.35-5.37 (m, 1H), 7.13-7.38 (m, 7H), 7.70-7.73 (m, 2H), 7.90-7.94 (m, 1H), 8.32 (s, 1H); MS (DCl/NHs) m/z 527.00. Example 14C 2-hydroxyethyl4-[({[(1R)-5-ter^butyl-2,3-dmydro-lif-mden-l-yl]aniino}carbonyl)amino]- 1/f-indazole-l-carboxylate In a 250 ml Parr shaker flask was added Example 14B (6.0 g, 11.40 nunol), 20% Pd/C, and ethanol (100 ml). The vessel was pressurized to 60 psi with H2 gas and shaken at room temperature for 6 hours. The reaction was filter and concentrated in vacuo. The material was purified on Si02 with dicMoromethane/CHjOH (98/2) to give a white solid (4.18g) in 84%. !H NMR (DMSO-d6, 300MHz); 5ppm 1.32 (s, 9H), 1.86-1.93 (m, 2H), 2.57-2.63 (m, IH), 2.84-2.92 (m, IH), 2.96-3.01 (m, IH), 3.92-3.95 (m, 2H), 4.55-4.58 (m, 2H), 5.27-5.32 (t, J=7.12,14.58, IH), 7.28-7.31 (m, 2H), 7.52 (t, J=7.80,16.28, IH), 7.73 (d, J=7.72Hz, IH), 7.87 (d, J=8.48Hz, IH), 8.38 (s, IH); MS (DCI/NH3) m/z 437.00. Example 14D 2-[(di-ter^butoxyphosphoryl)oxy]emyl4-[({[(lJ?)-5-te^butyl-2,3-dmydro-lJY-inden-l-yl]ammo}carbonyl)amino]-l//-indazole-l-carboxylate To Example 14C (1.60 g, 3.70 mmol) was added methylene chloride (25 ml), tetrahydrofuran (25 ml), tetrazole (0.77 g, 11.0 mmol), 4-(dimemylamino)pyridine (0.18 g, 1.50 mmol) and di-tert-butyl diisopropyl-phosphoramidite (2.04 g, 7.30 mmol) (Aldrich) and the reaction was stirred at room temperature for 2 hours. The reaction was then cooled to 0°C and 30% hydrogen peroxide was added and the mixture was stirred for 2 hours at room temperature. The reaction was poured into a separatory funnel and washed with water, sat NaHCC>3, dried over Na2SC>4 and concentrated in vacuo. The mixture was purified by HPLC with acetonitrile and 0.1% trifiuoroacetic acid buffer to give a white solid in 48% yield. !H NMR (CD3OD, 300MHz); 5 ppm 1.32 (s, 9H), 1.45 (s,18H), 1.83-1.95 (m,2H), 2.52.66 (m, IH), 2.82-2.90 (m, IH), 3.92-3.06 (m, IH), 4.35-4.40 (m, 2H), 4.73-4.84 (m, 2H), 5.29 (t, J=7.26,14.68Hz, IH), 7.28-7.31 (m, 2H), 7.52 (t, J=8.13,16.27Hz, IH), 7.54 (d, J=8.14Hz, IH), 7.76 (d, J=7.80Hz, IH), 8.37 (s, IH); MS (DCI/NH3) m/z 629.00; Calc for C32H245N4O7P: C, 60.44; H, 7.26; N, 8.81. Found: C, 60.45; H, 7.26; N, 8.68. Example 15 3-(phosphonooxy)propyl4-[({[(liZ)-5-te7'/-butyl-2,3-dihydro-ljy'-inden-l- yl]ainmo}carbonyl)amino]-lfl-indazole-l-carboxylate Example 15A Carbonic acid 3-benzyloxy-propyl ester 4-nitro-phenyl ester To a 250 ml round bottom flask was added 3-benzyloxypropanol (8.24 g, 49.60 mmol) (Aldrich), 4-nitrophenyl chloroformate (10 g, 49.60 rmnol) (Aldrich), dichloromethane (100 ml) followed by the addition of pyridine (5.89 g, 79.10 mmol) and the reaction was stirred at room temperature for 12 hours. The reaction was diluted with 200 ml of dichloromethane was washed with IN HC1 (100 ml), sat NaHC03 (100 ml), dried (NaaSQj) and concentrated in vacuo. The reaction was purified on SiC>2 and eluted with hexane/ethyl acetate 4/1 to provide a yellow oil (8.26) in 50% yield. :H NMR (CDC13, 300 MHz); 8 ppm 2.03-2.11 (m, 2H), 3.62 (t, J=6.0,12.0Hz, 2H), 4.43 (t, J=6.0,12.0Hz, 2H), 4.53 (s, 2H), 7.26-7.37 (m, 7H), 8.26(d, J=9.0Hz, 2H); MS (DCI/NH3) m/z 332.0. Example 15B 3-(benzyloxy)propyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-lflr-inden-l-yl]arnmo}carbonyl)amino]-l/f:-indazole-l-carboxylate To a 250ml round bottom flask was added Example 56J (7.35g, 21.10mmol), anhydrous N,N-dimethylformamide (60ml) and potassium terf-butoxide (1M in tetrahydrofuran, 25.32ml) and the reaction mixture was stirred at room temperature for 1 hour. To the reaction mixture was added Example 15A (7.0g, 21.10mmol) at 0 °C, stirred for 12 hours while allowing to warm to room temperature. The reaction mixture was poured into a separatory funnel and extracted with ethyl acetate (500ml) and washed with H2O (200ml), brine (200ml), dried (Na2SC>4) and concentrated in vacuo. The mixture was purified on silica gel and eluted with hexane/ethyl acetate 1/1 to provide a white solid (4.96g) in 43% yield. *H NMR (CDCI3, 300MHz); 8 1.27 (s, 9H), 1.72-1.87 (m, IH), 2.07-2.21 (m, 2H), 2.51-2.61 (m, IH), 2.73-2.94 (m, 3H), 3.64 (t, J=5.77,16.95Hz, 2H), 4.49-4.68 (m, 4H), 5.34-5.39 (m, IH), 7.13-7.38 (m, 7H), 7.70-7.73 (m, 2H), 7.90-7.94 (m, IH), 8.32 (s, IH). DCI/NH3 m/z 540.00. Example 15C 3-hydroxypropyl4-[({[(12?)-5-te^butyl-23 l/Z-indazole-l-carboxylate In a 250 ml Pair shaker flask was added product of Example 15B (2.2g, 4.10 mmol), 20% Pd/C and ethanol (100 ml). The vessel was pressurized to 60 psi with H2 gas and shaken at room temperature for 6 hours. The reaction was filtered and concentrated in vacuo. The material was purified on SiC>2 with dichloromefoane/CEbOH (98/2) to give a white solid (1.57g) in 85%. !H NMR (CDC13, 300MHz); 8 ppml.28 (s, 9H), 1.81-2.08 (m, 2H), 2.41-2.52 (m, 3H), 2.77-2.87 (m, 1H), 2.91-3.01 (m, 1H), 3.55-3.68 (m, 2H), 4.49 (t, J=4.43, 11.82Hz, 2H),5.13-5.20 (m, 1H), 7.22-7.27 (m, 2H), 7.50 (t, J=8.14,16.28Hz, 1H),6.67 (d, J=9.13Hz, 1H), 7.89 (d, J=8.14Hz, 1H), 8.39 (s, 1H); MS (DCI/NH3) m/z 451.00. Example 15D 3-[(di-ter^butoxyphosphoryl)oxy]propyl4-[({[(lJ?)-5-ter^butyl-2,3-dihydro-li?-inden-l-yl]amino}carbonyl)amino]-lfl-indazole-l-carboxylate To the product from Example 15C (1.49 g, 3.30 mmol) was added methylene chloride (50 ml), tetrazole (0.70 g, 9.90 mmol), 4-(dimemylamino)pyridine (0.16 g, 1.30 mmol) and di-tert-butyl diisopropyl-phosphoramidite (3.15 g, 9.90 mmol) (Aldrich) and the reaction was stirred at room temperature for 2 hours. The reaction was then cooled to 0°C and 30% hydrogen peroxide was added and the mixture was stirred for 2 hours at room temperature. The reaction was poured into a seperatory funnel and washed with water, sat NaHCO^, dried over Na2SC>4 and concentrated in vacuo. The mixture was purified on Si02 with hexane/ethyl acetate (1/1) to give a white solid (2.12g) in 97% yield. *H NMR (CDCI3, 300 MHz); 8 ppm . 1.22 (s, 9H), 1.30(s, 18H), 2.17-2.27 (m, 1H), 2.58-2.65 (m,lH), 2.81-2.94 (m, 1H), 3.20-3.51 (m, 2H), 3.72-3.78 (m, 2H), 4.12-4.18 (m, 2H), 4.59 (t, J=6,78,13.22,2H), 5 42 (t, J=7.46,12.24Hz, 1H), 7.19-7.32 (m, 2H), 7.45 (t, J=8.14,16.24Hz, 1H), 7.76 (d, J=8.48Hz, 1H), 7.95 (d, J=7.80Hz, 1H), 8.47 (s, 1H); MS (DCI/NH3) m/z 642.00. Example 15E 3-(phosphonooxy)propyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-li?-inden-l-yl]ammo}carbonyl)amino]-lJy-indazole-l-carboxylate To the product from Example 15D (2.12 g, 3.30 mmol) in a 250 ml round bottom flask was added acetonitrile (40 ml) and 0.1% trifluoroacetic acid in water (40 ml) and the reaction was stirred at room temperature for 4 days. Every 24 hours 0.5ml of trifluoroacetic acid was added until day four. The reaction was concentrated to give a white powder in 81 % yield. *H NMR (CDC13,300MHz); 8 ppm 1.32 (s, 9H), 1.88-1.92 (m, 1H), 2.22-2.26 (m, 2H), 2.57-2.63 (m, 1H), 2.84-2.90 (m, 1H), 2.96-3.32 (m, 1H), 4.21 (m, 2H), 4.65 (t, J=6.11, 12.55Hz, 2H), 5.29 (t, J=7.46,14.58Hz, 1H), 7.28-7.31 (m, 3H), 7.52 (t, J=8.14,16.28Hz, 1H), 7.73 (d, J=7.45Hz, 1H), 7.83 (d, J=8.48Hz, 1H), 8.36 (s, 1H); MS (DCI/NH3) m/z 531.00; Calc for C25H31N4O7P: C, 54.45; H, 5.59; N, 9.92. Found: C, 54.84; H, 5.88; N, 9.92. Example 16 ^-[(1R)-5-fert-butyl-2,3-dmydro-l/^mden-l-yl]-iV,-[l-(hyd^oxymemyl)-l^-indazol-4- yfjurea To a solution of compound from Example 56J (67 mg, 0.192 mmol) in 4 mL ethanol was added 0.5 mL of 37% aqueous formaldehyde solution. The mixture was stirred at room temperature for 3 days, and then was evaporated in vacuo. The crude product was purified by silica gel chromatography (96:4 dichloromethane:methanol, eluant) to afford a white solid, 24 mg (33%). !H NMR (d6-DMSO) 8 ppm 8.60 (s, 1H), 8.04 (s, 1H), 7.72 (dd; 1H; J=7.2,0.8 Hz), 7.27 (m, 4H), 6.67 (d, 1H, J=8.0 Hz), 6.64 (t, 1H, J=7.5 Hz), 5.66 (d, 2H, J=7.5 Hz), 5.15 (q, 1H, J=7.5 Hz), 2.87 (m, 2H), 2.43 (m, 1H), 1.82 (m, 1H), 1.28 (s, 9H); MS (ESf) m/z 379 (M+H). Example 17 {4-[({[(1R)-5-fe^butyl-2,3-dmydro-lif-mden-l-yl]amino}carbonyl)amino]-l//-indazol-l- yl}methyl acetate The product from Example 16 (50 mg, 0.132 mmol) and acetic anhydride (1 mL) were heated for 4 hours at 60°. The mixture was evaporated in vacuo and chromatographed on silica gel (65:35 hexane:ethyl acetate, eluant) to afford the desired product as a white solid, 12 mg (22%). lH NMR (d6-DMSO) 5 8.67 (s, IH), 8.16 (s, 1H), 7.75 (d, IH, J=7.5 Hz), 7.27 (m, 5H), 6.67 (d, IH, J=7.8 Hz), 6.34 (s, 2H), 5.15 (q, iH, J=6.7 Hz), 2.85 (m, 2H), 2.42 (m, IH), 2.02 (s, 3H), 1.85 (m, IH), 1.28 (s, 9H); MS (ESI*) m/z 421 (M+H), 443 (M+Na). Example 18 {4-[( {[(1R)-5-ter^-butyl-2,3-dihydro- liJ-inden-1 -yl]amino} carbonyl)amino]- lH-iadazol-1 - yl}methyl 3-hydroxypropanoate Example 18A 3- {[tert-butyl(diphenyl)silyl]oxy}propan-1 -ol To a solution of 1,3-propanediol (1.25 g, 16.4 mmol) in N,N-dhnethylformamide (50 mL) was added imidazole (2.23g, 32.8 mmol) and tert-butyldiphenylsilyl chloride (4.97 g, 18.1 mmol). The reaction was stirred for 3 days at room temperature, then was diluted with ethyl acetate and was washed with water and brine. Concentration in vacuo afforded the crude product as a thick colorless oil which was used directly in the next step. Example 18B 3- {[te/-r-butyl(diphenyl)silyl]oxy}propanoic acid Example 18A (~5.0 g, 16.4 mmol) was dissolved in acetone (700 mL) and then chilled in ice. Jones reagent (10 mL, prepared by dissolution of 26.72 g CrC>3 in 23 mL cone. H2SO4 and dilution to 100 mL with H2O) was added slowly. The reaction mixture was stirred in the ice bath for 10 minutes, then the acetone was removed in vacuo. Ethyl acetate was added, and this solution was washed several times with H2O and once with brine. The solution was dried over NaaSCU and was then evaporated in vacuo to afford a crude yellow oil, 5.9 g (quantitative). MS (ESI4) m/z 351 (M+Na); MS (EST) m/z 327 (M-H). Example 18C chloromethyl3-{[tert-butyl(diphenyl)silyl]oxy}propanoate The title compound was prepared from the compound of Example 18B using the procedure as described in Synth. Commun. 2003,33,1683. JH NMR (d6-DMSO) 5 7.58-7.64 (m, 4H), 7.37-7.48 (m, 6H), 5.88 (s, 2H), 3.80 (t, 2H, J=6.1 Hz), 2.68 (t, 2H, J=5.8 Hz), 0.96 (s, 9H). Example 18D {4-[({[(1R)-5-te^butyl-2,3-dihydro-l^-mden-l-yl]ammo}carbonyl)animo]-lF-mdazol-l- yljmethyl 3-hydroxypropanoate To a solution of compound from Example 56J (500 mg, 1.44 mmol) in N,N-dimethylformamide (8 mL) was added 60% NaH (65 mg, 1.63 mmol). The reaction was stirred at room temperature for 10 minutes and was then treated with Example 18C (1.35 g,~40% pure) in 3 mL N,N-dimethylformamide. The mixture was stirred overnight at 60°C and was then evaporated in vacuo. To this crude mixture in tetrahydrofuran (50 mL) in a polyethylene bottle was added hydrogen fluoride-triemylamine complex (3 mL). The reaction was stirred at room temperature for 5 hours and was then evaporated in vacuo. Chromatography on silica gel (97:3 dichloromethane:methanol to 94:6 dichloromethane:methanol) afforded the desired product as a white solid. JH NMR (d6-DMSO) 5 8.68 (s, IH), 8.16 (s, IH), 7.75 (dd; IH; J=7.5,1.0 Hz), 7.27-7.37 (m, 5H), 6.68 (d, IH, J=7.8 Hz), 6.35 (s, 2H), 5.15 (q, IH, J=6.9 Hz), 4.69 (t, IH, J=5.0 Hz), 3.60 (m, 2H), 2.73-3.01 (m, 2H), 2.44 (t, 2H, J=6.1 Hz), 1.78-1.92 (m, 2H), 1.28 (s, 9H); MS (ESf) m/z 451 (M+H). Example 19 (phosphonooxy)memyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-lfl"-inden-l- yl]amino} carbonyl)amino]-1 iif-indazole-1 -carboxylate Example 19A Thiocarbonic acid O-sec-butyl ester O-chloromethyl ester Sodium methoxide (11.5 g 0.2 moles) of 95% was added to 200 ml of methanol and the solution was cooled to 0 °C. Sec-butanethiol (21.4 ml, 0.2 mol) was then added dropwise and the solution stirred for 2 hours. The solvent was removed and the residue was evaporated from ether twice. 300 ml of diethyl ether was added to the residue and the mixture was cooled to -78 °C. Chloromethyl chloroformate (19 ml, 0.2 mol) in 75 ml of ether was added dropwise and the reaction mixture was allowed to warm to room temperature and then stirred for 18 hours. The reaction was filtered through celite and washed with ether. The filtrate was evaporated, resuspended in in ether and filtered through a silica plug, and the solvent was evaporated to give 29 g of a clear liquid. 'H NMR (300 MHz, CDC13) 5 ppm 0.94 (t, J=7.29 Hz, 3 H) 1.36 - 1.48 (m, 2 H) 1.60 -1.70 (m, 2 H) 2.89 - 2.95 (m, 2 H) 5.76 (s, 2 H). Example 19B Thiocarbonic acid O-sec-butyl ester O-iodomethyl ester Example 19A (6.0 g 33 mmol) in 45 mL of acetone was combined with (9.8 g 66 mmol) of sodium iodide and (0.3 g 3.3 mmol) of sodium bicarbonate and heated at 40 °C for 4 hours. 100 ml of diethyl ether was added and the mixture was washed with 10% sodium bicarbonate then 1% sodium thiosulfate until the organic phase was clear. The organic phase was dried with sodium sulfate and the solvent was evaporated. The residue was resuspended in pentane and the organic layer was washed with 10% sodium bicarbonate then 1% sodium thiosulfate. The organic phase was then dried with magnesium sulfate and the solvent was evaporated to give 7.3 g of a clear oil. lH NMR (300 MHz, CDC13) 8 ppm 0.93 (t, J=7.29 Hz, 3 H) 1.35 - 1.48 (m, 2 H) 1.58 -1.70 (m, 2 H) 2.88 - 2.94 (m, 2 H) 5.99 (s, 2 H). Example 19C 0-({[bis(benzyloxy)phosphoryl]oxy}methyl) 0-(sec-butyl) thiocarbonate The product of Example 19B (7.3 g, 27 mmoles) and tetrabutylammonium dibenzylphosphate (13.8 g, 26.6 mmol)were mixed in 20 ml of tetrahydrofuran and stirred at room temperature for 24 hours. The mixture was diluted with 100 mL of tetrahydrofuran, filtered through celite and the solvent was evaporated. The residue was resuspended in 200 mL of 20% ethyl acetate in hexane and the precipitate was filtered and washed with an additional 100 mL of 20% ethyl acetate. The organic filtrates were combined and the solvent was evaporated. Final product was obtained by flash chromatography on silica using 20% ethyl acetate in hexane. Fractions containing product were combined and the solvent was removed to give 8.7 g (78%) of a colorless oil. lH NMR (300 MHz, CDC13) 8 ppm 0.91 (t, J=7.29 Hz, 3 H) 1.31 - 1.45 (m, 2 H) 1.55 -1.65 (m, 2 H) 2.80 - 2.90 (m, 2 H) 5.07 (d, J=7.80 Hz, 4 H) 5.65 (d, J=13.90 Hz, 2 H) 7.34 (s, 10 H). Example 19D O-dibenzylphosphonooxymethylchloroformate 7.3 g (17 mmol) of the compound from Example 19C was cooled to 4°C. 1.7 mL (21 mmol) of sulfuryl chloride was added dropwise. Reaction was stirred at 4°C for an additional 20 minutes, the cooling bath was removed and the mixture was allowed to stir at room temperature for an additional 3 hours. Diethyl ether was added and then was evaporated under vacuum. The remaining oil was dried under high vacuum for 18 hours yielding 6.1 g (quantitative) of a colorless oil. !H NMR (300 MHz, CDC13) 5 ppm 5.08 (d, J=8.14 Hz, 4 H) 5.62 (d, J=14.24 Hz, 2 H) 7.35 (s, 10 H). Example 19E {|^is(benzyloxy)phosphoryl]oxy}memyl4-[({[(l/f)-5-?6!rt-butyl-2,3-dmydro-liy-inden-l-yl]ammb}carbonyl)ammo]4#-mdazole4-carboxylate 1.6 g (4.6 mmol) of compound from Example 56J in 15 mL of tetrahydrofuran was cooled to -40 °C in an acetonitrile dry ice bath. 1 mL (9.1 mmol) of 4-methylmorpholine was added, then 4.1 g (11 mmol) of compound from Example 19D was added dropwise. The reaction was stirred at -40 °C for 20 minutes then the ice bath removed and the reaction allowed to warm to room temperature. The mixture was diluted with 200 mL of diethyl ether, extracted 4 times with 25 mL of water, dried over magnesium sulfate, 2 mL of dimethylformamide was added and the ether removed by rotory evaporation leaving a clear oil which was purified by reverse phase HPLC with 0.1% trifluoroacetic acid in water and acetonitrile as mobile phases to provide 1.3 g of a white powder. JH NMR (400 MHz, DMSO-de) 5 ppm 1.31 (s, 9 H) 1.88 -1.98 (m, 1 H) 2.48 - 2.57 (m, 1 H) 2.87 (m, 1 H) 2.97 -3.05 (m, 1 H) 5.16 (d, J=7.98 Hz, 4 H) 5.26 (q, J=7.06 Hz, 1 H) 6.05 (d, J=14.73 Hz, 2 H) 6.79 (d, J=7.67 Hz, 1 H) 7.29 - 7.39 (m, 13 H) 7.55 (t, J=8.13 Hz, 1 H) 7.74 (d, J=8.29 Hz, 1 H) 8.01 (d, J=7.98 Hz, 1 H) 8.53 (s, 1 H) 8.97 (s, 1 H). MS(ESI) m/z 683.3 (M + H)+. Example 19F (phosphonooxy)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-li?-inden-l-yl]amino} carbonyl)amino]- lif-indazole-1 -carboxylate 1.3 g (1.9 mmol) of Example 19E in 150 mL of tetrahydrofuran was added to 0.7 g of 20% Pd(OH)2 on carbon, wet, under argon. The vessel was charged to 60 psi with hydrogen and reacted for 3.2 hours with shaking. The catalyst was removed by filtration and the solvent removed. The compound was purified by reverse phase HPLC with 0.1% trifluoroacetic acid in water and acetonitrile as mobile phases to obtain 0.3 g of title compound. JH NMR (300 MHz, DMSO-de) 8 ppm 1.28 (s, 9 H) 1.79 - 1.91 (m, 1 H) 2.41 - 2.48 (m, 1 H) 2.77 - 2.88 (m, 1 H) 2.91 - 3.01 (m, 1 H) 5.16 (q, J=7.35 Hz, 1 H) 5.84 (d, J=14.24 Hz, 2 H) 6.69 (d, J=7.80 Hz, 1 H) 7.25 - 7.33 (m, 3 H) 7.52 (t, J=8.14 Hz, 1 H) 7.72 (d, J=8.48 Hz, 1 H) 7.90 (d, J=7.80 Hz, 1 H) 8.44 (s, 1 H) 8.86 (s, 1 H)MS (DCI/NH3) m/z 503.2 (M + H)+. Example 20 3-{4-[({[(l^)-5-ter^butyl-2,3-dihydro-l#-mden^ yl}-3-oxopropyl dihydrogen phosphate Example 20A 3-{[bis(benzyloxy)phosphoryl]oxy}propanoic acid The water was removed in vacuo from 3-hydroxy-propionic acid and the residue dried twice from toluene. 0.8 g (8.9 mmol), and dissolved in 10 mL of dry tetrahydrofuran. 1 ml (9 mmol) of 4-methyl-morpholine was added, then 10 mL of a 1 M solution of tert-butyldimethylsilyl chloride in tetrahydrofuran was added and the mixture stirred at room temperature for 10 minutes. 5 g (14.5 mmol) of dibenzyl diisopropylphosphoramidite and 1.2 g (17.1 mmol) of tetrazole was premixed in 20 mL of tetrahydrofuran then added to the reaction mixture and allowed to react at room temperature for 30 minutes. The mixture was cooled to 0 °C in an ice bath, then 3.5 mis of 35% aqueous hydrogen peroxide was added and the mixture stirred for 30 minutes. 10 mL of 10% sodium bisulfite was added slowly then 200 mL of diethyl ether. The organic phase was washed three times with 10% potassium dihydrogen phosphate, dried over magnesium sulfate and the was solvent evaporated. Product was obtained by flash chromatography of the crude material on silica using hexanes and ethyl acetate (70:30). JH NMR (300 MHz, CDC13) 5 ppm 2.65 (t, J=6.10 Hz, 2 H) 4.26 (q, J=6.44 Hz, 2 H) 5.04 (d, J=8.14 Hz, 4 H) 7.33 (s, 10 H). MS (ESI) m/z 351.1 (M + H)+. Example 20B dibenzyl3-{4-[({[(1R)-5-te^buryl-2,3-dmydro-127-mden-l-yl]ammo}carbonyl)amino]-li/- indazol-1 -yl} -3-oxopropyl phosphate l.lg (3.1 mmol) of Example 20A in 8 mL of dichloromethane and 3.1 mL of a 1M solution of N,N'^cyclohexylcarbodiimide in dichloromethane were mixed and 1.0 g (2.9 mmol) of Example 56J in 8 mL of dimethylformamide was added. The mixture was allowed to react at room temperature for 18 hours. 200 mL of diethyl ether was added to the mixture and the organic phase was washed three times with water, dried over magnesium sulfate and the solvent removed. The product was isolated by flash chromatography on silica using hexanes and ethyl acetate (80:20). !H NMR (300 MHz, DMSO-ds) 5 ppm 1.28 (s, 9 H) 1.79 -1.92 (m, 1 H) 2.41 - 2.49 (m, 1 H) 2.77 - 2.89 (m, 1 H) 2.91 - 3.02 (m, 1 H) 3.56 (t, J=5.93 Hz, 2 H) 4.39 - 4.49 (m, 2 H) 5.01 (d, J=8.14 Hz, 4 H) 5.17 (q, J=7.23 Hz, 1 H) 6.70 (d, J=7.80 Hz, 1 H) 7.25 - 7.38 (m, 13 H) 7.52 (t, J=8.14 Hz, 1 H) 7.89 (t, J=8.14 Hz, 2 H) 8.41 (s, 1 H) 8.85 (s, 1 H).MS(ESI) m/z 681.5 (M + H)+. Example 20C 3-{4-[({[(1R)-5-tert-butyl-2,3-d^ydro-lfr yl}-3-oxopropyl dihydrogen phosphate 0.45 g (0.7 mmol) of Example 20B in 100 mL of tetrahydrofuran was added to 0.7 g of 20% Pd(OH)2 on carbon, wet, under argon. The vessel was charged to 60 psi with hydrogen and reacted for 3.2 hours with shaking. The catalyst was removed by filtration and the solvent was evaporated. The compound was purified by reverse phase HPLC with 0.1% trifluoroacetic acid in water and acetonitrile as mobile phases to obtain 0.15 g of title compound. !H NMR (300 MHz, DMSO-ds) 5 ppm 1.28 (s, 9 H) i.79 - 1.92 (m, 1 H) 2.41 -2.49 (m, 1 H) 2.76 - 2.88 (m, 1 H) 2.89 - 3.01 (m, 1 H) 3.53 (t, J=6.27 Hz, 2 H) 4.23 - 4.32 (m, 2 H) 5.17 (q, J=7.12 Hz, 1 H) 6.71 (d, J=7.80 Hz, 1 H) 7.25 - 7.33 (m, 3 H) 7.52 (t, J=8.14 Hz, 1 H) 7.89 (t, J=7.46 Hz, 2 H) 8.42 (d, J=0.68 Hz, 1 H) 8.86 (s, 1 H). MS(ESI) m/z 501.3 (M + H)+. Example 21 [({4-[({[(1R)-5-te^butyl-2,3-dmydro4^mden4-yl]ammo}carbonyl)amino]-li?-indazol-l- yl} carbonyl)oxy]methylphosphonic acid Example 21A Hydroxymethyl-phosphonic acid dibenzyl ester Charged an Emrys 5 mL process vial with 2.0 g (7.63 mmol) dibenzyl phosphite, 229 mg (7.63 mmol) paraformaldehyde powder, and 0.11 mL (0.76 mmol) triethylamine. The white mixture was heated in a microwave (Personal Chemistry) at 130° for 5 minutes. The crude oil was purified on silica gel, eluting with 50-100% ethyl acetate in hexane to provide 947mg (42% yield) of the title compound, a colorless oil. MS (ESI) m/z: 181.1,293.0 [M+H]+ !H NMR (DMSO-dg) 8: 3.83 (m, 2H), 5.02 (d, 4H), 5.50 (m, 1H), 7.37 (m, 10H). Example 21B (4-Nitro-phenoxycarbonyloxymethyl)-phosphonic acid dibenzyl ester Charged a round bottom flask with 20 mL dichloroethane, 947mg (3.24 mmol) of Example 21A, 718 mg (3.56 mmol) 4-nitrophenyl chloroformate, and 0.31 mL (3.89 mmol) pyridine. The reaction mixture was stirred at 0 °C for 40 minutes, treated with 50 mL ethyl acetate, filtered through a silica gel plug, rinsed with ethyl acetate, and concentrated. The crude oil was purified on silica gel with 30-70% ethyl acetate in hexane to provide 1.429g (97% yield) of the title compound. MS (EST) m/z: 181.0, 351.1, 458.1 [M+H]+ ^NMR (DMSO-de) 5:4.71 (d, 2H), 5.11 (d, 4H), 7.39 (m, 10H), 7.48 (d, 2H), 8.29 (d, 2H). Example 21C [bis(benzyloxy)phosphoryl]methyl4-[({[(1R)-5-/ert-butyl-2,3-dihydro-li/-inden-l-yl]ammo}carbonyl)amino]-lfl'-indazole-l-carboxylate Dissolved 990 mg (2.84 mmol) of Example 56J in 10 mL N,N-dimethylformamide solution, added 3.12 mL (3.12 mmol) 1.0M potassium tert-butoxide in tetrahydrofuran, stirred for.5 minutes at ambient temperature, then added 1.429 g (3.12 mmol) of Example 21B in 10 mL N,N-dimethylformamide. After 15 minutes, the solution was partitioned between 200 mL ethyl acetate and 200 mL H2O, dried the organic layer with brine and NaaSQt, and concentrated. The crude oil was purified on silica gel, eluting with 50-100% ethyl acetate in hexane to obtain 1.622 g (86%) of title compound as yellow foam. MS (ESI) m/z: 349.1, 667.30 [M+H]+ *H NMR (DMSO-de) 5: 1.28 (s,9H), 1.79-1.91 (m, IH), 2.41-2.47 (m, IH), 2.79-2.87 (m, IH), 2.91-3.01 (m, IH), 4.94 (d, 2H), 5.11-5.23 (m, 5H), 6.70 (d, IH), 7.27 (s, 2H), 7.29-7.41 (m, 1 IH), 7.45 (t, IH), 7.62 (d, IH), 7.89 (d, IH), 8.44 (s, IH), 8.86 (s, IH). Example 2 ID [({4-[({[(1R)-5-te^butyl-2,3-dmydro-l^-mden-l-yl]ammo}carbonyl)animo]-l/f-indazol-l- yl}carbonyl)oxy]methylphosphonic acid 1.5 g (2.25 mmol) of me compound from Example 21C was added to a mixture of 0.3 g 20% Pd(OH)2/C and 150 mL methanol in a stainless steel autoclave. The reactor was sealed and flushed with nitrogen, and then it was pressurized with hydrogen (60 psi). The mixture was stirred at ambient temperature for 90 minutes. Product precipitated, added 150 mL tetrahydrofuran to redissolve, catalyst was filtered off, washed with methanol and tetrahydrofuran, and the filtrate was concentrated to provide 1.08g (99%) of the title compound. MS (ESI) m/z: 485.21 [M-H]" !H NMR (DMSO-de) 5: 1.28 (s, 9H), 1.81-1.88 (m, IH), 2.42-2.48 (m, IH), 2.79-2.87 (m, IH), 2.91-3.01 (m, IH), 4.56 (d, 2H), 5.16 (q, IH), 6.69 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.50 (t, IH), 7.72 (d, IH), 7.89 (d, IH), 8.43 (s, IH), 8.85 (s, IH). Example 22 [( {4-[( {[(ll?)-5-tert-butyl-2,3-dihydro- lH-iadea-1 -yl]amino} carbonyl)amino]~ 1 #-indazol-1 -yl}carbonyl)oxy]methylphosphonic acid triethylamine salt Suspended 50.2mg (103umol) of compound from Example 21D in 10 mL methanol, added 10.4mg (103umol) triethylamine, stirred the colorless solution for 10 minutes at ambient temperature, concentrated and vacuum dried. Obtained 61 mg (100% yield) of the title compound as an off-white powder. *H NMR (methanol-dt) 8:1.29 (t, 9H), 1.32 (s, 9H), 1.90 (m, IH), 2.59 (m, IH), 2.89 (m, IH), 3.00 (m, IH), 3.16 (q, 6H), 4.54 (d, 2H), 5.29 (t, IH), 7.28 (s, 2H), 7.31 (s, IH), 7.52 (t, IH), 7.74 (d, IH), 7.97 (d, IH), 8.36 (s, IH). Anal Calcd for C23H27N4O6P • 1.0 triemylamine • 0.7 methanol: C, 58.47; H, 7.40; N, 11.48. Found: C, 58.46; H, 7.38; N, 11.44. Example 23 2-memoxyemyl4-[({[(1R)-5-te/^butyl-2,3-dmy^ liMndazole-1 -carboxylate The title compound was prepared using the procedure as described in Example 21C, substituting methoxyethoxychloroformate for Example 21B. MS (EST) m/z: 450.78 [M+H]+ 'HNMRtDMSO-dg) 5:1.28 (s, 9H), 1.86 (m, IH), 2.48 (m, IH), 2.85 (m, IH), 2.96 (m, IH), 3.33 (s, 3H), 3.72 (m, 2H), 4.57 (m, 2H), 5.15 (q, IH), 6.67 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.50 (t, IH), 7.67 (d, IH), 7.88 (d, IH), 8.40 (s, IH), 8.84 (s, IH). Anal Calcd for C25H3oN404: C, 66.65; H, 6.71; N, 12.44. Found: C, 66.22; H, 6.75; N, 12.25. Example 24 (2,2-dimemyH>dioxolan-4-yl)memyM yl]amino}carbonyl)amino]-li/-indazole-l-carboxylate Example 24A Carbonic acid 2,2-dimethyl[l,3]dioxolane-4-ylmethyl ester 2,5-dioxo-pyrrolidin-l-yl ester To a solution of (2,2-dimethyl-[l,3]dioxolan-4-yl)-methanol (0.4 g, 3.0 mmol) in acetonitrile (10 mL) was added carbonic acid bis-(2,5-dioxo-pyrrolidin-l-yl) ester (1.15 g, 4.5 mmol) and Iriemylamine (0.84 mL, 6.0 mmol). After stirring at ambient temperature for 10 min, me mixture was concentrated at reduced pressure, sat. NaHC03 (50 mL)was added, and the solution was extracted with ethyl acetate and organic phase was separated and concentrated to obtain 1.0 g of crude product that was used without further purification in the next step. MS (APCI) m/z: 273 [M+H]+ 'H NMR (DMSO-dg) 5:4.50 (m, IH), 4.40-4.29 (m, 2H), 4.04 (m, IH), 3.73 (dd, J=6.0 and 9.0 Hz, IH), 2.80 (s, 4H), 1.35 (s, 3H), 1.30 (s, 3H). Example 24B (2^-dimemyl4,3-dioxolan-4-yl)methyl4-[({[(1R)-5-ter^bu1yl-2,3-dmydro-lF-inden-l-yl]arruno}carbonyl)amino]-l^'-indazole-l-carboxylate The title compound was prepared using the procedure as described in Example 21C, substituting Example 24A for Example 21B. MS (EST) m/z: 507.14 [M+H]+- lH NMR (DMSO-ds) 5: 1.28 (s, 9H), 1.30 (s, 3H), 1.35 (s, 3H), 1.86 (m, IH), 2.48 (m, IH), 2.85 (m, IH), 2.96 (m, IH), 3.84 (dd, IH), 4.10 (dd, IH), 4.45 (m, 3H), 5.15 (q, IH), 6.67 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.50 (t, IH), 7.69 (d, IH), 7.88 (d, IH), 8.40 (s, IH), 8.83 (s, IH). Anal Calcd for C28H34N4O5 • 1.4H20: C, 63.24; H, 6.97; N, 10.53. Found: C, 63.16; H, 6.60; N, 10.90. Example 25 (2-oxo^,3-daoxolan-4-yl)methyl4-[({[(1R)-5-te^butyl-2,3-dihydro-l/ir-inden-l- yl]amino} carbonyl)amino]- liZ-indazole-1 -carboxylate Example 25A Carbonic acid 2,5-dioxo-pyrrolidin-l-yl ester 2-oxo-[l,3]dioxolan-4-ylmethyl ester The title compound was prepared using the procedure as described in Example 24A, substituting 4-hydroxymethyl-[l,3]dioxolan-2-one for (2,2-dimethyl-[l,3]dioxolan-4-yl)-methanol. MS (APCI) m/z: 259 [M+H]+ !H NMR (DMSO-de) 8: 5.13 (m, IH), 4.61 (m, 3H), 4.31 (dd, J=6.0 and 9.0 Hz, IH), 2.80 (s, 4H). Example 25B (2-oxo-l,3-6Uoxolan-4-yl)memyl4-[({[(1R)-5-te^butyl-2,3-dihydro-liy-inden-l-yl]amino}carbonyl)ammo]-liJ-mdazole-l-carboxylate The title compound was prepared using the procedure as described in Example 21C, substituting Example 25A for Example 2 IB. MS (EST) m/z: 492.93 [M+H]+ !H NMR (DMSO-dg) 8:1.28 (s, 9H), 1.86 (m, IH), 2.48 (m, IH), 2.85 (m, IH), 2.96 (m, IH), 4.44 (dd, IH), 4.66 (m, 3H), 5.15 (q, IH), 5.24 (m, IH), 6.68 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.51 (t, IH), 7.64 (d, IH), 7.89 (d, IH), 8.42 (s, IH), 8.85 (s, IH). Anal Calcd for CzeHzsN^ • O.8H2O: C, 61.60; H, 5.89; N, 11.05. Found: C, 61.62; H, 5.66; N, 11.07. Example 26 2-hydroxyemyl4-[({[(lJ?)-5-fe^butyl-2,3-dihydro-li^-mden-l-yl]arnino}carbonyl)amino]- 1/f-indazole-l-carboxylate Example 26A 2-(benzyloxy)emyl4-[({[(liJ)-5-tert-butyl-2,3-dihydro-lH-indeR-l- yl] amino} carbonyl)amino]-l/Mndazole-1 -carboxylate The title compound was prepared using the procedure as described in Example 21C, substituting benzyloxyethoxychloroformate for Example 21B MS (ESI) m/z: 525 [M-H]+ !H NMR (DMSO-ds) 8:1.28 (s, 9H), 1.86 (m, IH), 2.44 (m, IH), 2.82 (m, IH), 2.95 (m, IH), 3.82 (m, 2H), 4.61 (m, 2H), 4.96 (s, IH), 5.15 (m, IH), 6.67 (d, J=4.5 Hz,lH), 7.38-7.25 (m, 9H), 7.48 (t, J=4.5 Hz, IH), 7.70 (d, J=6.0 Hz, IH), 7.90 (d, J=6.0 Hz, IH), 8.40 (s, IH), 8.84 (s, IH). Example 26B 2-hydroxyethyl 4-[({[(lJR)-5-terr-butyl-2,3-dihydro-l//-inden-l -yl]amino} carbonyl)amino]- 177-indazole-l -carboxylate Example 26A (0.41 g, 0.77 mmol) and 20% Pd(OH)2/C (0.42 g, 0.6 mmol) in ethyl acetate (10 mL) was hydrogenated at ambient temperature at 50 psi for 2 hours. The resulting mixture was filtered through a nylon filter and concentrated to obtain the title compound (0.29 g, 86%). MS (ESI) m/z: 437.0 [M+H]+ *H NMR (DMSO-de) 8:1.28 (s, 9H), 1.86 (m, IH), 2.48 (m, IH), 2.85 (m, IH), 2.95 (m, IH), 3.82 (q, 2H), 4.46 (dd, 2H), 5.00 (t, IH), 5.15 (q, IH), 6.67 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.49 (t, IH), 7.69 (d, IH), 7.87 (d, IH), 8.40 (s, IH), 8.84 (s, IH). Anal Calcd for C24H28N4O4: C, 66.04; H, 6.47; N, 12.84. Found: C, 65.63; H, 6.54; N, 11.94. Example 27 2-(benzyloxy)-2-oxoethyl4-[({[(1R)-5-terf-butyl-2,3-dihydro-li/-inden-l- yl]amino}carbonyl)amhio]-li7-indazole-l-carboxylate Example 27A (2,5-Dioxo-pyrrohdin-l-yloxycarbonyloxy)-acetic acid benzyl ester The title compound was prepared using the procedure as described in Example 24A, substituting hydroxy-acetic acid benzyl ester for (2,2-dimethyl-[l,3]dioxolan-4-yl)-methanol. Example 27B 2-(berizyloxy)-2-oxoemyl44({[(1R)-5-tert-buryl-2,3-dihydro-li7-inden-l-yljamino} carbonyl)amino]- li7-indazole-1 -carboxylate The title compound was prepared using the procedure as described in Example 21C, substituting the compound from Example 27A for the compound from Example 21B MS (ESI) m/z: 541.29 [M+H]+ 'H NMR (DMSO-d6) 8:1.28 (s, 9H), 1.86 (m, IH), 2.47 (m, IH), 2.85 (m, IH), 2.96 (m, IH), 5.17 (m, 3H), 5.25 (s, 2H), 6.69 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.38 (m, 5H), 7.51 (t, IH), 7.68 (d, IH), 7.88 (d, IH), 8.45 (s, IH), 8.87 (s, IH). Anal Calcd for C31H32N4O5: C, 68.87; H, 5.97; N, 10.36. Found: C, 66.93; H, 5.05; N, 9.98. Example 28 2-{[(benzyloxy)carbonyl]ammo}e%14-[({[(1R)-5-ter^butyl-2,3-dihydro-l^-inden-l- yl]ammo}carbonyl)ammo]-l#-indazole-l-carboxylate Example 28A Carbonic acid 2-benzyloxycarbonylamino-ethyl ester 2,5-dioxo-pyrrolidin-l-yl ester The title compound was prepared using the procedure as described in Example 24A, substituting (2-hydroxy-ethyl)-carbamic acid benzyl ester for (2,2-dimethyl-[l,3]dioxolan-4-yl)-methanol. MS (APCI) m/z: 337 [M+H]+ Example 28B 2-{[(berizyloxy)carbonyl]animo}emyl4-[({[(l/?)-5-fert-butyl-2,3-dmydro-lif-inden-l-yl]amino} carbonyl)amino]- lff-indazole-1 -carboxylate The title compound was prepared using the procedure as described in Example 21C, substituting compound from Example 28A for the compound from Example 2 IB. MS (ESI) m/z: 570.33 [M+H]+ *H NMR (DMSO-d6) 5: 1.28 (s, 9H), 1.85 (m, IH), 2.48 (m, IH), 2.85 (m, IH), 2.95 (m, IH), 3.45 (q, 2H), 4.47 (t, 2H), 5.01 (s, 2H), 5.15 (q, IH), 6.67 (d, IH), 7.27 (s, 2H), 7.32 (m, 6H), 7.47 (t, IH), 7.55 (m, IH), 7.65 (d, IH), 7.87 (d, IH), 8.39 (s, IH), 8.83 (s, IH). Anal Calcd for C32H35N5O5 • 0.9H2O: C, 65.60; H, 6.33; N, 11.95. Found: C, 65.60; H, 5.97; N, 11.81. Example 29 [({4-[({[(1R)-5-te^butyl-2,3-dmydro-li^^ yl}carbonyl)oxy] acetic acid The title compound was prepared using the procedure as described in Example 26B, substituting Example 27B for Example 26 A. MS (ESI) m/z: 451.20 [M+H]+ *H NMR (DMSO-d6) 8:1.28 (s, 9H), 1.86 (m, IH), 2.45 (m, IH), 2.85 (m, IH), 2.94 (m, IH), 4.98 (s, 2H), 5.18 (q, IH), 6.68 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.52 (t, IH), 7.69 (d, IH), 7.88 (d, IH), 8.43 (s, IH), 8.86 (s, IH), 13.38 (br s, IH). Anal Calcd for C24H26N4O5 • 0.8H2O: C, 62.00; H, 5.98; N, 12.05. Found: C, 62.13; H, 5.78; N, 11.79. Example 30 2-andnoethyl4-[({[(l^)-5-ter^butyl-2,3-dihydro-lJy-inden-l-yl]amino}carbonyl)amino]- indazole-1-carboxylate hydrochloride A mixture of the product from Example 28B (0.53 g, 0.93 mmol) and 10% Pd/C (0.053 g, 0.047 mmol) in methanol (50 mL) and cone. HC1 (86 uL, 1.02 mmol) was hydrogenated under 60 psi of hydrogen gas at ambient temperature for lh. The resulting mixture was filtered and concentrated to obtain title compound (0.47 g, quantitative yield). :H NMR (DMSO-de) 8:1.28 (s, 9H), 1.84 (m, IH), 2.46 (m, IH), 2.85 (m, IH), 2.94 (m, IH), 4.65 (dd, 2H), 5.18 (q, IH), 6.96 (d, IH), 7.26 (s, 2H), 7.31 (s, IH), 7.51 (t, IH), 7.69 (d, IH), 7.91 (d, IH), 8.02 (br s, 2H), 8.59 (s, IH), 9.19 (s, IH). JH NMR (methanol-dO 8:1.32 (s, 9H), 1.91 (m, IH), 2.59 (m, IH), 2.90 (m, IH), 3.00 (m, IH), 3.45 (dd, 2H), 4.71 (dd, 2H), 5.30 (t, IH), 7.28 (s, 2H), 7.32 (s, IH), 7.57 (t, IH), 7.67 (d, IH), 7.90 (d, IH), 8.48 (s, IH). MS (ESI) m/z: 436.2 [M+H]+ Anal Calcd for C24H29N5O3 • HC1 • 1.8 H20: C, 57.15; H, 6.71; N, 13.88. Found: C, 57.21; H, 6.55; N, 13.60. Example 31 2-ethoxy-2-oxoethyl 4-[({[(l^)-5-tert-butyl-2,3-dihydro-lJ?-inden-l- yl] amino} carbonyl)amino]- lff-indazole-1 -carboxylate Example 31A (4-Nitro-phenoxycarbonyloxy)-acetic acid ethyl ester The title compound was prepared using the procedure as described in Example 21B, substituting hydroxy-acetic acid ethyl ester for Example 21A. JH NMR (DMSO-d6) 5: 8.36 (m, 2H), 7.57 (m, 2H), 4.90 (s, 2H), 4.20 (q, J=7.5 Hz, 2H), 1.22 (t, J=7.5 Hz, 3H). Example 3 IB 2-ethoxy-2-oxoethyl 4-[({[(li2)-5-ter/-butyl-2,3-dihydro-l^r-inden-l -yl]ammo}carbonyl)amino]-l/f-indazole-l-carboxylate The title compound was prepared using the procedure as described in Example 21C, substituting compound from Example 31A for the compound from Example 21B. MS (ESI) m/z: 479.27 [M+H]+ *H NMR (DMSO-dg) 8:1.24 (t, 3H), 1.28 (s, 9H), 1.86 (m, 1H), 2.48 (m, 1H), 2.85 (m, 1H), 2.94 (m, 1H), 4.20 (q, 2H), 5.09 (s, 2H), 5.18 (q, 1H), 6.69 (d, 1H), 7.28 (s, 2H), 7.31 (s, 1H), 7.52 (t, 1H), 7.69 (d, 1H), 7.88 (d, 1H), 8.45 (s, 1H), 8.88 (s, 1H). Anal Calcd for C26H30N4O5 • 0.4 H20: C, 64.29; H, 6.39; N, 11.53. Found: C, 64.22; H, 6.23; N, 11.46. Example 32 (diethoxyphosphoryl)methyl4-[({[(liJ)-5-tert-butyl-2,3-dmydro-lfir-inden-l- yl]amino} carbonyl)arnino]-177-indazole-l -carboxylate Example 32A (4-Nitro-phenoxycarbonyloxymethyl)-phosphonic acid diethyl ester The title compound was prepared using the procedure as described in Example 21B, substituting hydroxymethyl-phosphonic acid diethyl ester for Example 21 A. *H NMR (DMSO-de) 8: 8.38 (d, J=l 1.0 Hz, 2H), 7.60 (d, J-l 1.0 Hz, 2H), 4.63 (d, 7.5 Hz, 2H), 4.10 (m, 4H), 1.24 (t, J=6.0 Hz, 6H). Example 32B (diethoxyphosphoiyl)methyl4-[({[(1R)-5-te^butyl-2,3-dihydro-l/f-inden-l- yl]amino} carbonyl)amino]-1 J^-indazole-1 -caiboxylate The title compound was prepared using the procedure as described in Example 21C, substituting Example 32A for Example 21B. MS (ESI) m/z: 543.3 [M+H]+. *H NMR (DMSO-d6) 5: 1.26 (s, 6H), 1.28 (s, 9H), 1.86 (m, IH), 2.47 (m, IH), 2.85 (m, IH), 2.96 (m, IH), 4.15 (m, 4H), 4.84 (d, 2H), 5.15 (q, IH), 6.70 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.52 (t, IH), 7.67 (d, IH), 7.88 (d, IH), 8.44 (s, IH), 8.87 (s, IH). Anal Calcd for CzyHss^OgP • 0.4 H20: C, 58.99; H, 6.56; N, 10.19. Found: C, 59.08; H, 6.40; N, 10.01. Example 33 2-(diemylammo)-2-oxoemyl4-[({[(l^)-5-fe^buryl-2,3-dmydro-lH-inden-l- yl]ann^o}carbonyl)amino]-liy-indazole-l-carboxylate Example 33A Carbonic acid diethylcarbamoylmethyl ester 4-nitro-phenyl ester The title compound was prepared using the procedure as described in Example 21B, substituting N,N-diethyl-2-hydroxy-acetamide for Example 21A. *H NMR (DMSO-de) 8: 8.38 (d, J=11.0 Hz, 2H), 7.57 (d, J-11.0 Hz, 2H), 5.0 (s, 2H), 3.20 (m, 4H), 1.12 (m 6H). Example 33B 2-(diemylammo)-2-oxoemyl4-[({[(li2)-5-te^butyl-2,3-dinydro-l^-inden-l- yl]ammo}carbonyl)amino]-l/f-indazole-l-carboxyIate The title compound was prepared using the procedure as described in Example 21C, substituting Example 33A for Example 21B. MS (ESI) m/z: 506.32 [M+H]+ JH MMR (DMSO-ds) 5:1.05 (t, 3H), 1.18 (t, 3H), 1.28 (s, 9H), 1.86 (m, IH), 2.48 (m, IH), 2.85 (m, IH), 2.96 (m, IH), 5.18 (m, 3H), 6.68 (d, IH), 7.28 (s, 2H), 7.31 (s, IH), 7.50 (t, IH), 7.70 (d, IH), 7.87 (d, IK), 8.42 (s, IH), 8.86 (s, IH). Anal Calcd for C28H35N5O4 • 0.7 H20: C, 64.90; H, 7.08; N, 13.51. Found: C, 65.04; H, 7.13; N, 13.41. xample 34 2-oxopropyl4-[({[(1R)-5-te^butyl-23-dihydro-lH-mden-l-yl]amino}carbonyl)amino]-lJY- indazole-1 -carboxylate Example 34A Carbonic acid 4-nitro-phenyl ester 2-oxo-propyl ester The title compound was prepared using the procedure as described in Example 2IB, substituting l-hydroxy-propan-2-one for Example 21 A. lK NMR (DMSO-de) 8: 8.35 (d, J=l 1.0 Hz, 2H), 7.58 (d, J-11.0 Hz, 2H), 5.00 (m 2H), 2.16 (s, 3H). Example 34B 2-oxopropyl4-[({[(1R)-5-te^butyl-2,3-dmydro-li^-mden-l-yl]ammo}carbonyl)animo]-li7- indazole-1-carboxylate The title compound was prepared using the procedure as described in Example 21C, substituting Example 34A for Example 2 IB. MS (ESI) m/z: 449.17 [M+H]+ *H NMR (DMSO-de) S: 1.28 (s, 9H), 1.86 (m, IH), 2.23 (s, 3H), 2.47 (m, IH), 2.85 (m, IH), 2.96 (m, IH), 4.84 (d, IH), 5.17 (q, IH), 5.40 (d, IH), 6.69 (d, IH), 7.23 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.39 (t, IH), 7.82 (d, IH), 8.23 (s, IH), 8.71 (s, IH). Anal Calcd for C25H28N4O4 • 0.3 H20: C, 66.15; H, 6.35; N, 12.34. Found: C, 66.14; H, 6.25; N, 12.46. Example 35 2-(acetyloxy)ethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-liJ-mden-l- yl]ammo}carbonyl)amino]-lfl-indazole-l-carboxylate Example 35A Acetic acid 2-(4-nitro-phenoxycarbonyloxy)-ethyl ester The title compound was prepared using the procedure as described in Example 21B, substituting acetic acid 2-hydroxy-ethyl ester for Example 21A. !H NMR (DMSO-de) 8: 8.38 (d, J=11.0 Hz, 2H), 7.59 (d, J-11.0 Hz, 2H), 4.46 (m 2H), 4.12 (m, 2H), 2.05 (s, 3H). Example 35B -(acetyloxy)ethyl 4-[({[(1R)-5-tert-butyl-2,3:dihydro-lif-inden-l-yl]amino}carbonyl)amino]-lfl'-indazole-l-carboxylate The title compound was prepared using the procedure as described in Example 21C, substituting Example 35A for Example 2 IB. MS (ESI) m/z: 479.27 [M+H]+ JH NMR (DMSO-de) 8:1.28 (s, 9H), 1.86 (m, IH), 2.05 (s, 3H), 2.48 (m, IH), 2.85 (m, IH), 2.96 (m, IH), 4.41 (m, 2H), 4.65 (m, 2H), 5.15 (q, IH), 6.69 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.51 (t, IH), 7.66 (d, IH), 7.88 (d, IH), 8.41 (s, IH), 8.86 (s, IH). Anal Calcd for C2&H30N4O5 • 0.4 H20: C, 64.29; H, 6.39; N, 11.53. Found: C, 64.29; H, 6.48; N, 11.24. Example 36 2-(dimemoxyphosphoryl)emyl4-[({[(li?>5-te^butyl-2,3-dihydro-liy-inden-l- yl]ammo}carbonyl)amino]-l/f-indazole-l-carboxylate Example 36A [2-(4-Nitro-phenoxycarbonyloxy)-ethyl]-phosphonic acid dimethyl ester The title compound was prepared using the procedure as described in Example 2 IB, substituting (2-hydroxy-ethyl)-phosphonic acid dimethyl ester for Example 21A. MS (ESI) m/z: 320 [M+H]+ !H NMR (DMSO-de) 8: 8.35 (d, J=11.0 Hz, 2H), 7.56 (d, J=11.0 Hz, 2H), 4.40 (m, 2H), 3.70 (s, 3H), 3.66 (s, 3H), 2.37 (m, 2H). Example 36B 2-(dimethoxyphosphoryl)ethyl 4-[({[(l^)-5-/ert-butyl-2,3-dihydro-lfl-inden-l- yl]ammo}carbonyl)amino]-l^f-indazole-l-carboxylate The title compound was prepared using the procedure as described in Example 21C, substituting Example 36A for Example 21B. MS (ESI) m/z: 529.25 [M+H]+ *H NMR (DMSO-dg) 8: 1.28 (s, 9H), 1.85 (m, IH), 2.42 (m, 3H), 2.85 (m, IH), 2.94 (m, IH), 3.64 (s, 3H), 3.68 (s, 3H), 460 (m, 2H), 5.15 (q, IH), 6.68 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.50 (t, IH), 7.71 (d, IH), 7.87 (d, IH), 8.40 (s, IH), 8.84 (s, IH). Anal Calcd for C26H33N4O6P • 0.5 H20: C, 58.09; H, 6.38; N, 10.42. Found: C, 58.16; H, 6.37; N, 10.30. Example 37 PCT/US2006/041739 [bis(benzyloxy)phosphoryl]mel!iyl4-[({[(l^)-5-/ert-butyl-2,3-dihydro-lJy-inden-l-yl]ainino}carbonyl)amino]-liy-indazole-l-carboxylate Example 37A (4-Nitro-phenoxycarbonyloxymemyl)-phosphonic acid dibenzyl ester The title compound was prepared using the procedure as described in Example 2 IB, substituting hydroxymethyl-phosphonic acid dibenzyl ester for Example 21 A. MS (ESI) m/z: 458 [M+H]+ ^NMRfDMSO-dfiJS: 8.30 (d,J=l 1.0 Hz, 2H), 7.51 (d, J==11.0Hz,2H), 7.37 (m, 10H), 5.13 (d, J=7.5 Hz, 4H), 4. 72 (d J=8.0 Hz, 2H). Example 37B |>is(benzyloxy)phosphoryl]memyl4-[({[(1R)-5-fe^butyl-2,3-dmydro-liI-mdeh-l-yl]ammo}carbonyl)amino]-lJy'-indazole-l-carboxylate The title compound was prepared using the procedure as described in Example 21C, substituting Example 37A for the compound from Example 21B. MS (ESI) m/z: 349.1, 667.30 [M+H]+ 'HNMRpMSO-de) 5: 1.28 (s, 9H), 1.79-1.91 (m, IH), 2.41-2.47 (m, IH), 2.79-2.87 (m, IH), 2.91-3.01 (m, IH), 4.94 (d, 2H), 5.11-5.23 (m, 5H), 6.70 (d, IH), 7.27 (s, 2H), 7.29-7.41 (m, 11H), 7.45 (t, IH), 7.62 (d, IH), 7.89 (d, IH), 8.44 (s, IH), 8.86 (s, IH). Anal Calcd for C37H39N4O6P: C, 66.66; H, 5.90; N, 8.40. Found: C, 66.56; H, 5.76; N, 8.55. Example 38 [({4-[({[(1R)-5-fer^bu1yl-2,3-dmydro-liy-mden-l-yl]amino}carbonyl)amino]-liy-mdazol-l- yl}carbonyl)oxy]methylphosphonic acid The title compound was prepared using the procedure as described in Example 26B, substituting Example 37B for Example 26A. MS (ESI) m/z: 485.21 [M-H]" *H NMR (DMSO-de) 5:1.28 (s, 9H), 1.81-1.88 (m, IH), 2.42-2.48 (m, IH), 2.79-2.87 (m, IH), 2.91-3.01 (m, IH), 4.56 (d, 2H), 5.16 (q, IH), 6.69 (d, IH), 7.27 (s, 2H), 7.31 (s, IH), 7.50 (t, IH), 7.72 (d, IH), 7.89 (d, IH), 8.43 (s, IH), 8.85 (s, IH). !H NMR (methanol-d^ 8: 1.32 (s, 9H), 1.89 (m, IH), 2.59 (m, IH), 2.87 (m, IH), 3.01 (m, IH), 4.72 (d, 2H), 5.29 (t, IH), 7.28 (s, 2H), 7.32 (s, IH), 7.54 (t, IH), 7.75 (d, IH), 7.90 (d, IH), 8.41 (s, IH). Anal Calcd for CzsHaT^OfiP • 0.6 H20: C, 55.55; H, 5.72; N, 11.27. Found: C, 55.63; H, 5.77; N, 10.99. Example 39 [({4-[({[(l£)-5-te^butyl-2,3-dih^ yl}carbonyl)oxy]methylphosphonate, triethylamine salt To a suspension of Example 38 (0.05 g, 0.1 mmol) in methanol (10 mL) was added triemylamine (0.01 g, 0.1 mmol) and the mixture stirred 10 minutes at ambient temperature, concentrated under reduced pressure and drying in vacuum to provide 0.06 g (100%) of title compound. *H NMR (methanol-cU) 5: 1.29 (t, 9H), 1.32 (s, 9H), 1.90 (m, IH), 2.59 (m, IH), 2.89 (m, IH), 3.00 (m, IH), 3.16 (q, 6H), 4.54 (d, 2H), 5.29 (t, IH), 7.28 (s, 2H), 7.31 (s, IH), 7.52 (t, IH), 7.74 (d, IH), 7.97 (d, IH), 8.36 (s, IH). Anal Calcd for C23H27N4O6P • 1.0 triethylamine • 0.7 methanol: C, 58.47; H, 7.40; N, 11.48. Found: C, 58.46; H, 7.38; N, 11.44. Example 40 [({4-[({[(lii)-5-tert-bu1yl-2,3-Kimydro-l^^ yl}carbonyl)oxy]methylphosphonic acid, diemylaminoethanol salt The title compound was prepared using the procedure as described in Example 39, substituting diemylaminoethanol for triemylamine. *H NMR (methanol-dU) 8:1.30 (t, 6H), 1.32 (s, 9H), 1.90 (m, IH), 2.59 (m, IH), 2.89 (m, IH), 3.00 (m, IH), 3.20 (m, 6H), 3.83 (dd, 2H), 4.54 (d, 2H), 5.29 (t, IH), 7.28 (s, 2H), 7.31 (s, IH), 7.52 (t, IH), 7.74 (d, IH), 7.98 (d, IH), 8.36 (s, IH). Anal Calcd for C23H27N4O6P • 0.8 CeHisNO • 0.65 methanol: C, 56.85; H, 6.98; N, 11.19. Found: C, 56.85; H, 7.01; N, 11.23. Example 41 [({4-[({[(l#)-5-te^butyl-2,3-dmydro-li7-mden4-yl]am yl}carbonyl)oxy]methylphosphonic acid, triemanolamine salt The title compound was prepared using the procedure as described in Example 39, substituting triethanolamine for triemylamine. !H NMR (methanol-dU) 8:1.31 (s, 9H), 1.90 (m, IH), 2.59 (m, IH), 2.89 (m, IH), 3.00 (m, IH), 3.37 (m, 6H), 3.87 (dd, 6H), 4.54 (d, 2H), 5.29 (t, IH), 7.28 (s, 2H), 7.31 (s, IH), 7.52 (t, IH), 7.74 (d, IH), 7.98 (d, IH), 8.36 (s, IH). Anal Calcd for C23H27N4O6P • 1.1 C6H15NO3 • 0.7 methanol: C, 54.08; H, 6.93; N, 10.61. Found: C, 54.08; H, 6.82; N, 10.67. xample 42 [({4-[({[(l£)-5-f^butyl-2,3-2 and eluted with ethyl acetate to give a oily white solid in 62%. *H NMR (DMSO-de, 300MHz); 8 1.28 (s, 9H), 1.79-1.91 (m, IH), 2.38 (s, 6H), 2.73-3.01(m, 3H), 4.04 (s, 2H), 5.13-5.20 (m, IH), 6.70 (d, J=7.8Hz, IH), 7.27-7.54 (m, 3H), 7.51 (t, J=8.14,16.28, IH), 7.88 (t, J=8.48,13.91 Hz, 2H), 8.38 (s, IH), 8.84 (s, IH). DCI/NH3 m/z 434. Example 60 AT-[(l#)-5-ter^utyl-2,3-dmydro-li^^ yl]urea, hydrochloride salt The solid from Example 59 was taken up in ethyl acetate/diethyl ether (1/10) (20mL) and 2N HC1 in diethyl ether (2.0eq) was added dropwise and the mixture was stirred for 5 minutes. The reaction was concentrated in vacuo to give the title compound as a white solid. 'HNMRODMSO-ds, 300MHz); 81.28 (s, 9H), 1.77-1.83 (m, IH), 2.42-2.53 (m, IH), 2.73-2.94 (m, 2H), 2.97 (s, 6H), 5.02 (s, 2H), 5.14-5.21 (m,lH), 7.25-7.35 (m, 4H), 7.58 (t, J=7.80, 15.94Hz, IH), 7.83 (d, J=8.14Hz, IH), 8.03 (d, J=8.14Hz, IH), 8.93(s, IH), 9.77 (s, IH). Calc for C25H3iN502"1.7HCl: C, 60.60; H, 6.65; N, 14.13. Found: C, 60.91; H, 6.87; N, 13.85. MS (DCI/NH3) m/z 434. Example 61 (i?)-l-(5-?ert-Butyl-2,3-dihydro-iii'-inden-l-yl)-3-(l-(2-(2-methoxyethoxy)acetyl)-/ff- indazol-4-yl)urea Example .61A 4-Nitrophenyl2-(2-methoxyethoxy)acetate 2-(2-methoxyethoxy)acetic acid (Alfa, 2.68 g, 20 mmol) was dissolved in dichloromethane (60 mL), and oxalyl chloride (5.2 mL, 60 mmol) was added with a few drops of dimethylformamide. The mixture was stirred for one hour, concentrated to a yellow slurry and dichloromethane (40 mL) was added. 4-nitrophenol (Aldrich, 2.78 g, 20 mmol) was dissolved in pyridine (2.4 mL, 30 mmol) and dichloromethane (60 mL), and then the (2-metiioxyethoxy)acetyl chloride solution was added and the mixture was stirred for one hour. A solution of 1:1 ethyl acetate:hexane was added which precipitated the salts, which were then filtered through a silica gel plug. The filtrate was concentrated to a yellow oil and chromatographed on silica gel with 0-to-60% ethyl acetate in hexane. Obtained 4.33 g (85% yield) of Example 61A as a yellow solid. lH NMR (300 MHz, DMSO-<&) 5 ppm 3.26 (s, 3H), 3.50 (m, 2H), 3.71 (m, 2H), 4.48 (s, 2H), 7.49 (d, /=9.15 Hz, 2H), 8.32 (d, J=9.15 Hz, 2H). MS (DCI) m/z 273.08 (M+]SfflU)+. Example 61B (J?)-l-(5-tert-Butyl-2,3-dmydro-7i7-mden-l-yl)-3-(l<2-(2-methoxyethoxy)acetyl)-iH- indazol-4-yl)urea Example 56J (1.74 g, 5.0 mmol) was dissolved in tetrahydrofuran (80 mL), and then potassium tert-butoxide (1.0 M in THF, 5.5 mL, 5.5 mmol) was added. The solution stirred for 5 minutes, Example 61A (1.40g, 5.5mmol) was added in tetrahydrofuran (20 mL), and the solution was stirred for another 15 minutes. Ethyl acetate was added, the salts precipitated, and the mixture was filtered through a silica gel plug. The filtrate was concentrated and chromatographed on silica gel using 0-to-35% ethyl acetate in dichloromethane as the eluent. Obtained 1.227g (53% yield) of Example 61B as a solid. JH NMR (300 MHz, DMSO-rf6) 8 ppm 1.28 (s, 9H), 1.85 (m, 1H), 2.45 (m, 1H), 2.82 (m, 1H), 2.96 (m, 1H), 3.27 (s, 3H), 3.53 (m, 2H), 3.75 (m, 2H), 4.98 (s, 2H), 5.16 (q, .7=7.34 Hz, 1H), 6.69 (d, .7=7.80 Hz, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.52 (t, /=7.97 Hz, 1H), 7.86 (d, 7=8.14 Hz, 1H), 7.89 (d, .7=7.79 Hz, 1H), 8.39 (s, 1H), 8.85 (s, 1H). MS (ESI) m/z 465.32 (M+H)+. Calcd for QseHraN^ • 0.22 Ethyl acetate • 0.15 H20: C 66.34, H 7.05, N 11.51; Found: C 66.32, H 6.63, N 11.45. Example 62 l-((i?)-5-te^Butyl-2,3-dihydro-;#-m^^ 4-yl)urea Example 62A 4-Nitrophenyl 3,5,5-trimethylhexanoate Dissolved 4-nitrophenol (Aldrich, 1.39 g, 10 mmol) in pyridine (1.2 mL, 15 mmol) and dichloromethane (50 mL), chilled to 0°C, then added 3,5,5-trimethylhexanoyl chloride (Aldrich, 1.9mL, lOmmol), warmed to ambient temperature and stirred for 1.5 hours. Added ethyl acetate, precipitated salts, and filtered through silica gel plug. Concentrated filtrate and chromatographed on silica gel with O-to-20% ethyl acetate in hexane. Obtained 2.79g (100% yield) of Example 62A as an oil. lK NMR (300 MHz, DMSO-2 eluting with 1% CH3OH in CH2CI2 to give Example 66G (3.7g) in 70% yield. MS(+APCI)m/z 245 (M+H)+. Example 66H 3-(Dimemylammo)propyl4-(3-(4-cyclopropyl-5-fluoro-2,3-dmydro-//7-inden-l-yl)ureido)-i/f-indazole- 1-carboxylate trifluoroacetate To a solution of Example 66F (0.24 g, 0.70 mmol) and Example 66G (0.335 g, 1.40 mmol) in N,N-dimethylformamide (10 mL) was added a solution of IN KO-t-Bu (0.8 mL, 0.80 mmol) and the mixture stirred 12 hours at ambient temperature. The resulting solution was concentrated and the residue was purified on reverse phase HPLC eluting with acetonitrile/0.1%TFA in H20 to give Example 66H (0.124 g) in 34%. JH NMR (300 MHz, CD3OD) § ppm 0.80-0.84 (m, 2H), 0.92-0.97 (m, 2H), 1.60-1.82 (m, IH), 1.86-2.12 (m, 2H), 2.28-2.38 (m, IH), 2.60-2.72 (m, IH), 2.97 (s, 6H), 3.40 (t, J=7.80,15.26Hz, 2H), 3.71 (t, J=6.44,13.22Hz, IB), 4.21 (t, JM6.10, 11.87Hz, IH), 4.61 (t, J=5.77,11.87Hz, 2H), 5.27 (t, J=7.46,14.58Hz, IH), 6.83-6.98 (m, IH), 7.14-7.18 (m, IH), 7.42-7.67 (m, 2H), 7.87-7.96 (m,lH),8.40(d,J=1.02Hz, IH). MS(+APCI)m/z 480 (M+H)+. Calcfor C26H30N5O3F:1.0TFA:C, 56.66; H, 5.26; N,11.80. Found: C, 56.84; H, 5.43; N, 11.92. Example 67 l-(4-Cyclopropyl-2,3-dmydro-7^-mden-l-yl)-3-(l-(2-(dimemylanmio)acetyl)-i^indazol-4- yl)urea trifluoroacetate Example 67A 4-Bromo-2,3-dihydro-/#-inden-l-one O-methyl oxime Methoxylamine hydrochloride (5.7 g, 68.2 mtnol) was added to 4-bromo-l-indanone (Aldrich, 13.477 g, 63.9 mmol) in pyridine (50 mL) and stirred for 3 hours at ambient temperature. Concentrated the mixture to a slurry, added ethyl acetate (200 mL), washed with IN hydrochloric acid (200 mL), dried with brine, jBltered through a silica gel plug, and concentrated the filtrate. Obtained 15.248 g (99% yield) of Example 67A. *H NMR (300 MHz, DMSO-4?) 8 ppm 2.83 (m, 2H), 2.96 (m, 2H), 3.91 (s, 3H), 7.25 (t, 7=7.80 Hz, IH), 7.57 (dd, 7=7.63, 0.84 Hz, IH), 7.61 (dd, 7=7.79, 1.01 Hz, IH). MS (DCI) m/z 241.90 (M+H)+. Example 67B 4-Cyclopropyl-2,3-dihydro-i/f-inden-l-one (9-methyl oxime Example 67A (1.92 g, 8.0 mmol) was added to a mixture of cyclopropylboronic acid (Aldrich, 893 mg, 10.4 mmol), potassium phosphate (5.94 g, 28.0 mmol), palladium(lT) acetate (90 mg, 0.4 mmol) and tricyclohexylphosphine (224 mg, 0.8 mmol) in toluene (32 mL) with water (1.6 mL). Heated the mixture at 100 °C for 3 hours on the microwave (Personal Chemistry). After cooling, the mixture was filtered through celite and rinsed with ethyl acetate. Concentrated the filtrate to an oil and chromatographed on silica gel with 0 tol0% ethyl acetate in hexane. Obtained 1.32g (82% yield) of Example 67B. !H NMR (300 MHz, DMSO-d6) 5 ppm 0.68 (m, 2H), 0.95 (m, 2H), 1.90 (m, IH), 2.82 (m, 2H), 3.05 (m, 2H), 3.88 (s, 3H), 6.90 (d, 7=7.46 Hz, IH), 7.18 (t, 7=7.63 Hz, IH), 7.36 (d, 7=7.80 Hz, IH). MS (DCI) m/z 202.09 (M+H)+. Example 67C 4-Cyclopropyl-2,3-dmydro-7i7-inden-l-arnine Example 67B (1.32 g, 6.56 mmol), Raney nickel (6.0 g), and 20% ammonia in methanol (40 mL) were shaken under hydrogen (60 psi) for 4 hours at ambient temperature. The catalyst was removed by filtration and the solvent evaporated under reduced pressure, giving 1.11 g (97% yield) of Example 67C. !H NMR (300 MHz, DMSO-4?) 5 ppm 0.61 (m, 2H), 0.90 (m, 2H), 1.58 (dq, 7=12.29, 8.45 Hz, IH), 1.85 (m, 3H), 2.35 (m, IH), 2.70 (dt, 7=16.05, 7.97 Hz, IH), 2.97 (ddd, 7=15.85, 8.73, 3.22 Hz, IH), 4.17 (t, 7=7.46 Hz, IH), 6.66 (d, 7=7.80 Hz, IH), 7.09 (m, 2H). MS (DCI) m/z 174.12 (M+H)+. Example 67D 1 -(4-CyclopropyI-2,3 -dihydro-Ttf-inden-1 -yl)-3-(iif-indazol-4-yl)urea Example 66E (2.13 g, 6.41 mmol) was added to Example 67C (1.11 g, 6.41 mmol) in diisopropylethylamine (1.12 mL, 6.41 mmol) and dimethylformamide (50 mL) at ambient temperature. After 1 hour the mixture was diluted with water (200 mL), the resulting white precipitate was filtered off, washed with water and air dried. Obtained 2.44 g (98% yield) of methyl 4-(3-(4-cyclopropyl-2,3-dihydro-7i7-inden-l-yl)ureido)-//?-indazole-l-carboxylate as a white solid. Suspended 1.94 g of this intermediate in triethylamine (1.4 mL, 10.0 mmol), methanol (150 mL) and water (15 mL). Refluxed the mixture for 30 minutes, cooled to ambient temperature, diluted with water (500 mL), collected the white precipitate by filtration, rinsed with water and air-dried. The wet cake was freeze-dried to constant weight, yielding 1.60 g (97% yield) of Example 67D. *H NMR (300 MHz, DMSO-2 eluting with ethyl acetate. The material was taken up in ethyl acetate/diethyl ether (22 mL, 1/10) and 2M HC1 in diethyl ether (2.0 eq) was added and the solution stirred at room temperature for 5 minutes. The material was concentrated in vacuo to give Example 68E as a white solid (0.192 g) in 42%. *H NMR (300 MHz, CD3OD) S. ppm 0.62-0.66 (m, 2H), 0.91-0.96 (m, 2H), 1.84-1.93 (m, 2H), 2.54-2.62 (m, IH), 2.79-2.87 (m, IH), 2.94-3.01 (m, IH), 3.11 (s, 6H), 5.02 (s, 2H), 5.25-5.29 (m, IH), 6.93-6.96 (m, 2H), 7.23 (d, J=7.67Hz, IH), 7.37 (t, J=8.28,15.96Hz, IH), 7.56 (d, J=7.98Hz, IH), 7.74 (d, J=7.98Hz, IH), 8.49 (s, IH). MS(+APCI)m/z 418 (M+H)+. Calc for C24H27N502:1.4 HC1:C, 61.52; H, 6.11; N,14.95. Found: C, 61.87; H, 6.15; N.14.82. Example 69 l-(l-(2-(Pimemylammo)acetyl)-/ff-mdazol-4-yl)-3-(4-(3,3-dimemylbutyl)-5- dihydro-1H-inden-1 -yl)urea Example 69A 4-(3,3-Dimemylbut-l-ynyl)-5-fluoro-2,3-dmydro-i/^mden-l-oneO-memyloxime Example 66B (1.29 g, 5.0 mmol) was added to a mixture of 3,3-dimethyl-l-butyne (Aldrich, 0.75 mL, 6.0 mmol), Pd(Ph3P)2Cl2 (175 mg, 0.25 mmol), copper-O- iodide (48 mg, 0.25 mmol) and triphenylphosphine (262 mg, 1.0 mmol) in triemylarnine (7.5 mL) and dimethylformamide (2.5 mL). The mixture was heated to 130 °C for 20 minutes on the microwave (Personal Chemistry). Additional 3,3-dimethyl-l-butyne (1.5 mL, 12.0 n*mol) was added via syringe, then continued heating for another 20 minutes. After cooling, the mixture was filtered through celite, rinsed with ethyl acetate, and the filtrate concentrated an oil. The material was chromatographed on silica gel with 0 to 10% ethyl acetate in hex yielding 1.32 g of impure product. Repeated chromatography on silica gel with 0 to 100% dichloromethane in hexane, to give 1.089g (84% yield) of Example 69A. 'H NMR (300 MHz, DMSO-rf2-dimethyl-l,3-dioxolan-4-yl)methyl4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-1 -yl] amino} carbonyl)amino]- lH-indazole-1 -carboxylate; (2-oxo-l,3-dioxolan-4-yl)methyl4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]amino}carbonyl)amino]-lH-indazole-l-carboxylate; 2-(benzyloxy)ethyl 4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]amino} carbonyl)amino]- lH-indazole-1 -carboxylate; 2-hydroxyethyl4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]amino}carbonyl)arnino]-lH-indazole-l-carboxylate; 2-(benzyloxy)-2-oxoethyl4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]aniino}carbonyl)amino]-lH-indazole-l-carboxylate; 2-{[(tenzyloxy)carbonyl]amino}ethyl4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]ammo}carbonyl)arnino]-lH-indazole-l-carboxylate; [({4-[({[(lR)-5-tert-butyl-2J3-dihydro-H-inden-l-yl]animo}carbonyl)amino]-lH-indazol-1 -yl} carbonyl)oxy] acetic acid; 2-aminoethyl4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]animo}carbonyl)arnino]-lH-indazole-l-carboxylate hydrochloride; 2-ethoxy-2-oxoethyl4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]amino} carbonyl)amino]-lH-indazole-1 -carboxylate; (diemoxyphosphoryl)methyl4-[({[(li?)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]arnino}carbonyl)amino]-liy-indazole-l-carboxylate; 2-(diethylamino)-2-oxoethyl4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l- yl]amino}carbonyl)amino]-lH-indazole-l-carboxylate; 2-oxopropyl4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl] amino} carbonyl)amino]-1 H-indazole-1 -carboxylate; 2-(acetyloxy)ethyl4-[({[(lR)-5-tert-butyl-2,3-diIiydro-lH-inden-l-yl]amino}carbonyl)amino]-lH-indazole-l-carboxylate; 2-dimethoxyphosphoryl)ethyl4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yljamino} carbonyl)arnino]- lH-indazole-1 -carboxylate; [bis(benzyloxy)phosphoryl]methy14-[({[(lR)-5-tert-butyl-2,3-dibydro-lH-inden-l yl]amino} carbonyl)amino]- lH-indazole-1-carboxylate; [({4-[({[(lR)-5-tert-butyl-2,3-dihydro-H-inden-l-yl]amino}carbonyl)amino]-lH-indazol-1 -yl} carbonyl)oxy]methylphosphonic acid; [({4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]ainino}carbonyl)amino]-lH-indazol-l-yl}carbonyl)oxy]methylphosphonate, triethylamine salt; [({4^({[(lR)-5-tert-bu1yl-2>3-dihydro-lH-inden-l-yl]amino}carbonyl)amino]-lH-indazol-l-yl}carbonyl)oxy]methylpb.osphonic acid, diethylaminoethanol salt; [({4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]amino}carbonyl)amino]-lH-indazol-l-yl}carbonyl)oxy]methylphosphonic acid, triethanolamine salt; [({4-[({[(lR)-5-tert-buryl-2,3-dihydro-lH-mden-l-yl]amino}carbonyl)amino]-lH-indazol-l-yl}carbonyl)oxy]methylphosphonic acid, piperazine salt; [({4-[({[(lR)-5-tert-buryl-2,3-ddydro-lH-inden-l-yl]amino}carbonyl)amino]-lH-indazol-l-yl}carbonyl)oxy]methylphosphonic acid, N-methyl-D-glucamine salt; N-[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]-N'-[l-(2-hydroxy-3-methoxypropyl)-1 H-indazol-4-yl]urea; N-[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]-N,-[2-(2-hydroxy-3-methoxypropyl)-2H-indazol-4-yl]urea; methyl 3-{4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl] amino} carbonyl)amino] - lH-indazol-1 -yl} -2-hydroxypropanoate; methyl 3-{4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]amino}carbonyl)aniino]-2H-mdazol-2-yl}-2-hydroxypropanoate; tert-butyl 3-{4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]amino}carbonyl)amino]-lH-indazol-l-yl}-2-hydroxypropylcarbamate; 3-{4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]ammo}carbonyl)amino]-lH- indazol-l-yl}-2-hydroxypropanoic acid; 3-{4-[({[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-yl]amino}carbonyl)amino]-2H-indazol-2-yl}-2-hydroxypropanoic acid; N-[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]-N,-[2-(2-hydroxy-3-morpholin-4-ylpropyl)-2H-indazol-4-yl]urea; N-[(lR)-5-tert-butyl-2,3-dihydro-lH-inden-l-yl]-N,-[l-(2-hydroxy-3-morpholin-4-ylpropyl)- lH-iiidazol-4-yl]urea; N-[(lR)-5-tert-butyl-253-dihydro-lH-inden-l-yl]-N'-{l-[(4-methylpiperazin-l-yl)carbonyl]-lH-indazol-4-yl}urea; N-[(lR)-5-tert-butyl-2)3-dihydro-lH-inden-l-yl]-N,-{2-[(4-methylpiperazin-l-yl)carbonyl]-2H-indazol-4-yl}urea; N-[(lR)-5-t6rt-butyl-2J3-dihydro-lH-inden-l-yL]-N,-[l-(N,N-dimethylglycyl)-lH- . indazol-4-yl]urea; N4(lR)-5-tert-butyl-2,3-dihydro-lH-Inden-l-yl]-N'-[l-(N,N-dimethylglycyl)-lH-indazol-4-yl]urea, hydrochloride salt; ((R)-l-(5-tert-butyl-2,3-dihydro-lH-inden-l-yl)-3-(l-(2-(2-methoxyethoxy)acetyl)-1 H-indazol-4-yl)urea; l-((R)-5-tert-butyl-23-dihydro-lH-indenlyl)-3(l-(3,5,5-trimethylhexanoyl)-lH-indazol-4-yl)urea; 2-ethymexyl4-(3-((R)-54ert-butyl-23-dihydro4H-inden-l-yl)ureido)-lH-indazole-l carboxylate; (R)-l-(l-(2-(2-butoxyethoxy)acetyl)-lH-indazol-4-yl)-3-(5-tert-butyl-2,3-dihydro-lH-inden-l-yl)urea; methyl 4-(3-(7-fluoro-2,2-dime1hylchroman-4-yl)ureido)-lH-indazole-l-carboxylate; 1 -(7-fluoro-2,2-dimethylchroman-4-yl)-3-( 1 -(2-methoxyethyl)- lH-indazol-4-yl)urea; 3-(dimethylamino)propyl4-(3-(4-cyclopropyl-5-fluoro-2,3-dihydro-lH-inden-l-yl)ureido)- lH-indazole-1 -carboxylate; l-(4-cyclopropyl-23-dihydro-lH-inden-l-yl)0-(l-(2-(dimethylarnino)acetyl)-lH-indazol-4-yl)urea trifluoroacetate; l-(5-cyclopropyl-2,3-dihydro-lH-inden-l-yl)-3-(l-(2-(dime1iiylarriino)acetyl)-lH-indazol-4-yl)urea hydrochloride; l-(l<2-(dimethylammo)acetyl)4H-indazol-4-yl)-3-(-4(3,3-dimethylbutyl)-5-fluoro- 2,3-dihydro- lH-inden-1 -yl)urea; (R)-l-(4-cyclopropyl-5-fluoro-2,3-dihydro-lH-inden-l-yl)-3-(l-(2-(dimethylamino)acetyl)-lH-indazol-4-yl)urea; (R)-l-(5-tert-butyl-2J3-dihydro-lH-inden-l-yl)-3-(l-(2-(methylamino)acetyl)-lH-indazol-4-yl)urea hydrochloride; 4-[3-(7-trifluoromethyl-chroman-4-yl)-ureido]-mdazole-l-carboxylic acid methyl ester; l-(l-(2-(dimemylammo)acetyl)4H-mdazol-4-yl)-3-(7-(trifluoromethyl)chroman-^ yl)urea; methyl4-({[(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)amino]carbonyl}amino)-ljy-indazole-1-carboxylate; and 1 -(8-tert-butylclriroman-4-yl)-3-( 1 -(2-(dimethylamino)acetyl)-1 H-indazol-4-yl)urea hydrochloride. 38. A pharmaceutical composition comprising a therapeutically effective amount of one or more compound of formula (I) as described in claim 1, or a therapeutically acceptable salt, solvate, or combination thereof, and a pharmaceutically acceptable carrier. 39. A method of treating or preventing disorders that may be ameliorated by inhibiting TRPVl activity in a mammal comprising administering a therapeutically effective amount of one or more compounds of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof. 40. A compound of formula (I) according according to claim 1 for use in the manufacture of a medicament for the treatment or prevention of a disease or condition that may be ameliorated by inhibiting TRPVl activity. 41. A compound according to claim 36 wherein the disease or disorder is associated with pain, inflammation, urinary incontinence and bladder dysfunction. 42. A method of treating or preventing a disease or disorders associated with neuropathic pain, inflammatory pain, or both, which method comprises administering a therapeutically effective amount of a compound of formula (I) according to claim 1 or aphaimaceutically acceptable salt thereof. 43. A method of treating or preventing a disease or disorder associated with bladder overactivity or urinary incontinence, or both, which method comprises administering a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof. 44. The compound of claim 2 of formula (Formula Removed) 45. The compound of claim 2 of formula (Formula Removed) 46. The compound of claim 20 of formula (Formula Removed) The compound of claim 20 of formula (Formula Removed)